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The Role of Neuroinflammation in Regulating the Age-Related Decline in Neurogenesis
Adam D. Bachstetter
ABSTRACT
Adult neurogenesis, is a lifelong process by which relatively few cells are added into two
restricted regions of the brain. Integration of the cells into the existing neuronal circulatory, with
the unique properties involved in the maturation of these cells, is possibly critical to the
acquisition and retrieval of new memories. With the chronological aging of the organism a
process of cellular senescence occurs throughout the body; a portion of which is independent of
primary alterations to the stem cells; instead, it appears to be dependent on the environment
where the cells reside, and is in part regulated by inflammation. Microglia, the resident immune
cells in the brain, are neuroprotective but chronic activation of the microglia, such as the chronic
activation that occurs with advanced age, can promote neurotoxic inflammation. However, it not
clear if the aged-related increase in neuroinflammation is at least partly responsible for the aged
related decrease in neurogenesis. To address the involvement in neuroinflammation in regulating
neurogenesis we used 3 different potential therapeutically relevant manipulations. The first was a
targeted approach directed at disrupting the synthesis of Interleukin-1β (IL-1β), which is a
proinflammatory cytokine that is consistently found elevated in the aged brain. The second was a
cell therapy approach in which human umbilical cord blood cells were injected into the systemic
circulation. The final approach was directed at a chemokine system, fractalkine/CX3CR1, which
has been shown as an important paracrine signal, from neurons that regulates the activation state
of microglia. While the three approaches used to manipulate, aging-rodent model system were
different, a consistent finding was reached in all three studies. In the aged brain, microglia which
are the predominate produces of IL-1β, negatively regulate neurogenesis. When IL-1β is
decreased or microglia activation is decreased, neurogenesis can be partially restored in the
aged brain. The results of these studies, demonstrate a key role for microglia in regulating the
neurogenic neiche, which are amendable to therapeutic manipulations.

vi

Introduction
Aging is the backdrop in which many neurodegenerative disease occur, including Alzheimer's
disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). As our
population ages, there is a pressing need to develop therapeutic interventions for age-related
neurodegenerative diseases. Not only is this true for the patient, but also for the sake of those
who will care for those suffering from a neurodegenerative disease.
Alterations in neural plasticity are associated with aging; however, recent studies have
demonstrated that the age-related alterations in neural plasticity are due to regional synaptic
alterations and not neuron loss (for review see: (Burke and Barnes, 2006)). One aspect of neural
plasticity is adult neurogenesis. Adult neurogenesis is the term used for a process, first described
in 1965, which results in the addition of new neurons in the adult brain (Altman and Das, 1965a).
The addition of new neurons is complementary to synaptogenesis, and adds another form of
neural plasticity. Neurogenesis is one of the possible mechanisms that could be utilized, as a
potential ‘reservoir’ of neural plasticity, to increase the quality of life of our aging population.
However, it is an important to consider when designing therapeutic strategies for our aging
population, with and without neurodegenerative diseases, that alterations occur to neural
plasticity as a result of age, and therefore the response to a therapeutic may be less efficacious in
the elderly.
Adult neurogenesis has been found in humans as old as 72 years of age (Eriksson et al.,
1998). However, considerably less is known about adult neurogenesis in humans compare to
rodents. In rodents, adult neurogenesis has now been extensively studied, and it is now well
accepted that neurogenesis occurs in at least two germinal centers in the brain, the
subventricular zone (SVZ) and the subgranlar zone (SGZ) of the hippocampal dentate gyrus (DG)
(for review see: (Ming and Song, 2005; Zhao et al., 2008)).
The process of Adult Neurogenesis
There are five phases of hippocampal neurogenesis: (1) The first phase is proliferation of
neural stem/progenitor cells (NPCs) which occurs in a region called SGZ, which is defined as a
two cell diameter band occurring on the hilus side of the granule cell layer (GCL). (2) The second
phase is the survival of the proliferating NPCs. During this phase the number of surviving neurons
can vary greatly depending on the strain of animals used and can be as great as ~ 75% or a few
as 25% of the amount of proliferating cells (Kempermann et al., 1997a). (3) The third phase,
occurring in concert with the second phase, is the differentiation of the newly born cells. In this
phase the majority of cells do become neurons, with a smaller percentage becoming astrocytes
1

and oligodendrocytes. (4) The fourth phase involves migration of the neurons into the GCL; with
most of the migration occurring around the first week (Kempermann et al., 2003a). (5) Finally, the
fifth phase involves the functional maturation of the neurons in the granule cell layer which occurs
around four weeks of age, but some cells may take weeks or even months longer to fully mature
(van Praag et al., 2002). It has also been demonstrated that those adult born neurons that survive
after 4 weeks will likely be present at least 11 months later (Kempermann et al., 2003a). The
majority of the decrease in neurogenesis with age appears to occur mostly in the first phase
through a decrease in proliferation (Drapeau and Nora Abrous, 2008). Survival of the newly born
cells appears to be unaffected by age. Maturation of the new born cells, particularly in developing
a mature neuronal phenotype and migrating into the GCL, does seem to be affected by age
(Drapeau and Nora Abrous, 2008).
Non-Cell-Autonomous Changes Regulating Neurogenesis
In many pathological conditions, including AD and PD, neurogenesis is dramatically affected
by the pathology (Hoglinger et al., 2004; Verret et al., 2007; Zhang et al., 2007; Nuber et al.,
2008). Neurogenesis is also significantly decreased with age (Kuhn et al., 1996; Kempermann et
al., 2002; Kronenberg et al., 2006a). The majority of the suppression of neurogenesis with age
appears to be a function of the microenvironment(niche) and is not NPC autonomous (reviewed
in:(Zhao et al., 2008). Moreover, the pool of NPCs appears to be intact with respect to the total
numbers of available NPCs (Hattiangady and Shetty, 2008), providing more evidence that that
the neurogenic niche is at least partly responsible for the decrease in neurogenesis with age.
Cellular senescence has been known to occur with age since the 1960s (Hayflick and
Moorhead, 1961), but the importance of the cellular senescence within the aged stem cell niche
has only recently become an area of active interest. A clear example of the importance of the
extrinsic or systemic influences on the stem cell niche was demonstrated in the stem cells that
are found in the muscle, called satellite cells. Like the neural stem cells, the satellite cells in the
muscle lose the potential to regenerate damaged tissue with age. In an elegant experiment, when
aged rats were exposed to the systemic environment of a young rat by parabiosis the satellite
cells were rejuvenated in the aged rats as demonstrated by an increase in the proliferation rate.
Conversely, in young rats the exposure to the circulation of the aged rats caused a decrease in
the regenerative potential of the satellite cells (Conboy et al., 2005), again supportive of an
extrinsic/circulating factor that is influencing the proliferation of the stem cells in the aged animals.
It is not clear whether the mechanism involved in the effect in the muscle would hold true in the
brain, but the implication is that the aged environment is detrimental to stem cell function. This
also holds true for even the most pluripotent of stem cells: the embryonic stem cells. When
embryonic stem cells are transplanted into aged tissue they are not able to repair damaged tissue
as well as when transplanted into young tissue (Carlson and Conboy, 2007).
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Many changes occur to the aged organisms which are known to negatively impact
neurogenesis (for review see (Drapeau and Nora Abrous, 2008)). However, there is little known
about the role of neuroinflammation in regulating the age-related decline in neurogenesis.
Neuroinflammation is known to negatively impact neurogenesis (Ekdahl et al., 2003; Monje et al.,
2003). It is known that neuroinflammation is elevated in aging and AD (Akiyama et al., 2000;
Krabbe et al., 2004). The following chapters will begin to clarify the role of neuroinflammation in
the age-related decline in neurogenesis.
Inflammation in Aging and Disease
Inflammation is an active process with the purpose of removing or inactivating potentially
damaging agents or damaged tissue. The inflammatory response is typified acutely by pain, heat,
redness, swelling, and loss of function. Following removal of the ‘danger signal’, a second
pathway is initiated with the role of tissue remodeling. In the central nervous system (CNS) the
inflammatory process must be well controlled. Since the majority of the CNS lacks the potential to
replace lost cells, an inflammatory response could be devastating resulting in neural tissue loss.
In general, inflammation is a beneficial with the primary result of removing the noxious agent and
remodeling the adjacent tissue. When inflammation is not well regulated following response to
‘danger signals’ a chronic pathology will result. It has been clearly shown that in the CNS there is
a marked increase in inflammatory activity associated with aging (Bodles and Barger, 2004;
Joseph et al., 2005; Mrak and Griffin, 2005). It is less clear what causes this inflammatory state.
Cytokines
Cytokines are low molecular weight proteins, with diverse biological activity due to the
various target cells and multiple response. Levels of specific cytokines expressed in the brain
increase as a function of age, even in the absence of a pathologic stimulus. For example, there is
a progressive increase in the expression of interleukin (IL)-1 and microglia activation with aging in
patients without a neurological disease (Roubenoff et al., 1998; Wilson et al., 2002), but to a
lesser extend then in patients with AD (Griffin et al., 1989). IL-6 levels also increase in the mouse
brain with advancing age (Godbout and Johnson, 2004). In the cerebellum of aged rats, tumor
necrosis factor-α (TNF-α) gene expression is dramatically increased compared to young rats
(Gemma et al., 2002). Immune response-related molecules and their receptors are expressed
throughout the brain, and recent research suggests that brain-derived immune factors disrupt
normal physiology and contribute to cognitive and behavioral dysfunction in neurologic disease
(Lynch, 1998; Pugh et al., 1999; Rachal Pugh et al., 2001; Barrientos et al., 2002).
IL-1β
IL-1β is one of the main inflammatory cytokines found in the CNS involved in
neuroinflammation (Shaftel et al., 2008). IL-1β is constitutively expressed in the brain,
synthesized by neuronal and/or glial cells, and released in response to a variety of stimuli,
including immune system activation (Benveniste, 1992; Rothwell et al., 1997) and in AD (Mrak
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and Griffin, 2001). IL-1β is a proinflammatory cytokine initially synthesized as an inactive
precursor that is cleaved by caspase-1 to generate the biologically mature 17-kDa form. In
rodents the enzymatic activity of caspase-1 is increased with normal aging (Gemma et al., 2005),
but mRNA expression is not altered (Sheng et al., 2001).
Virtually every cell type is affected by binding of IL-1β to the high affinity receptor, IL-1RI
(Rothwell et al., 1997; Dinarello, 1998). The IL-1β receptor expression is high in the hippocampus
as indicated by binding studies (Farrar et al., 1987; Takao et al., 1990). The IL-1 family
comprises three known ligands: IL-1α, IL-1β and IL-1ra. The biologic activity of IL-1β is
dependent on its interaction with IL-1RI and recruitment of the IL-1 receptor accessory protein (IL1Racp) (Sims, 2002). IL-1ra binds to IL-1RI but fails to associate with IL-1Racp, thereby acting
as a highly selective competitive receptor inhibitor. The only known function of IL-1ra is to
antagonize the biologic activity of IL-1.
IL-1β is a potent suppressor of neurogenesis but it is not completely clear how IL-1β
achieves this effect. IL-1β has been shown in vitro to be able to induce apoptosis in NPCs via
phosphorylation of the stress-activated protein kinase/Jun-amino-terminal kinase (SAPK/JNK)
pathway (Wang et al., 2007), thereby having a direct effect on the survival of the new born
neurons. The NF-κB/Iκκ pathway also seems to be critical in regulating the effects of IL-1β on
proliferation, possibly by decreasing Cyclin D1 expression (Koo and Duman, 2008). IL-1β, in
NPCs cultures also seemed to slightly favor differentiation into an astrocyte linage as determined
by the marker GFAP (Wang et al., 2007).
IL-1β is not alone in being able to directly affect NPC. Recently, Iosif et al. (2006) has
shown that the inflammatory cytokine TNF-α can also assert a direct effect on NPC proliferation.
TNF receptor 1 (TNF-R1) appears to have a regulatory function by blocking proliferation during
inflammation. This action occurs directly at the progenitor cells which express both TNF-R1 and
TNF-R2. TNF-R2 appears to play a neuroprotective role; although, its function is a little less clear
than that of TNF-R1 (Iosif et al., 2006).
Chemokines
Chemokines are small molecule (8-14 kDa) proteins that are classically defined as
chemotactic cytokines initially studied because of their role in leukocyte trafficking. Chemokines
are classified into 4 subfamilies – C; CC; CXC and CX3C – by the position of the conserved
cysteine residues near the NH2 terminus region of the protein (Bacon et al., 2002). The receptors,
by which chemokines exert their effects, are of the seven-transmembrane-domain G-proteincoupled receptor (GPCR) family. Chemokine GPCRs belongs to the class A rhodopsin-like
family, with the majority of the receptors being Gαi as indicated by the ability of pertussis toxin
(PTX) to inhibit the response of the receptors (Murphy, 1996). The extracellular NH2 terminus and
the three extracellular loops act to bind the chemokine ligand. The three intracellular loops and Cterminus act in signal transduction (Mellado et al., 2001).
4

Fractalkine/CX3CR1
In contrast to many other chemokines, fractalkine (FKN; CX3CL1; neurotactin) binds and
activates a single receptor, CX3CR1. Interactions between FKN and CX3CR1 contribute to
maintaining microglia in a resting phase, and partially controlling microglia induced neurotoxicity
(Cardona et al., 2006). FKN acts in vitro as an anti-inflammatory molecule by down-regulating IL1β, TNF-α, and IL-6 production (Zujovic et al., 2000; Zujovic et al., 2001). FKN can therefore, act
as a bridge between neurons and microglia, to regulate cytokine production and
neuroinflammation.
FKN is the only known member of the CX3C chemokine family (Bacon et al., 2002). FKN
is unique among chemokines; with cell surface presentation of the N-terminal chemokine domain
by a glycolated mucin-like stalk, that is anchored to membrane with a transmembrane and Cterminal cytoplasmic domain (Bazan et al., 1997; Pan et al., 1997). The chemokine domain can
be shed from the mucin stalk by a constitutive expressed metalloproteinase 10 (ADAM10)
(Hundhausen et al., 2003), or by an inducible cleavage by TNF-a converting enzyme (TACE /
ADAM17) (Garton et al., 2001). FKN is not expressed on peripheral blood leukocytes (Bazan et
al., 1997; Pan et al., 1997). FKN is expressed on endothelial cells(Bazan et al., 1997), epthelial
cells (Lucas et al., 2001), smooth muscle cells (Ludwig et al., 2002), dendritc cells (Papadopoulos
et al., 1999) and neurons (Pan et al., 1997; Harrison et al., 1998). FKN is most robustly
expressed in the CNS (Harrison et al., 1998). In isolated primary cultures neurons RT-PCR
showed FKN mRNA to be highest in neurons; however, low levels were detected in microglia and
astrocytes (Nishiyori et al., 1998).
In the CNS, FKN is predominantly expressed on neurons and is one of only two
chemokines that is constitutively expressed by neurons, the other being stromal cell-derived
factor-1 (SDF-1; CXCL12). SDF-1 is monomeric like FKN (Crump et al., 1997; Mizoue et al.,
1999). Recently it has been shown that SDF-1 has an important role in directly regulating adult
neurogenesis (Bhattacharyya et al., 2008; Kolodziej et al., 2008). It is not currently know if FKN
might have a similar role in regulating neurogenesis.
FKN also has a higher affinity for its receptor (CX3CR1) then other chemokine receptor
ligand pairs (Haskell et al., 2001). The exclusive receptor for FKN is a PTX sensitive GPCR,
named CX3CR1. Predominate expression of CX3CR1 in the CNS is found on microglia, which
suggest a paracrine regulation of microglia by neurons (Harrison et al., 1998). However,
expression of the receptor, is not sufficient to determine activity following ligation. In CD14+
moncoctyes less then 2% of cells that express CX3CR1 migrated to soluble FKN (Imai et al.,
1997). Moreover, of all the CX3CR1+ cells only 10% of the cells became activated after exposure
to soluble FKN (Imai et al., 1997). The adhesion properties of FKN appear to be independent of
signaling via the GPCR as PTX was no effect on adhesion (Imai et al., 1997).
The expression of CX3CR1 includes a subset of dendritic cells and natural killer cells,
5

peripheral blood monocytes and tissue macrophages including microglia (Jung et al., 2000). In
the CNS, CX3CR1 expression in vivo is limited to immune cells, namely microglia and not
astrocytes or neurons (Cardona et al., 2006; Combadiere et al., 2007). However, CX3CR1
expression has been shown in cultured neurons. Moreover, in vitro, FKN via CX3CR1 was able to
reduce excitotoxic cell death induced by glutamate and neurotoxicity induced by gp120IIIB +, an
HIV envelope glycoprotein (Meucci et al., 2000; Tong et al., 2000; Limatola et al., 2005).
Recent evidence has shown a role for CX3CR1 polymorphisms in the pathogenesis of
age-related macular degeneration (Tuo et al., 2004; Combadiere et al., 2007). There are at least
two common coding polymorphsims, V249I and T280M, in the CX3CR1 gene (Faure et al., 2000;
McDermott et al., 2001; Moatti et al., 2001), as well as, a single nucleotide poymorphims in the
promoter region of CX3CR1 (DeVries et al., 2003). The two SNPs CX3CR1 with a strong linkage
disequilibrium include: (1) A SNP at condon 249 that causes a switch from valine to isoleucine
(V249I). The other SNP results in a switch from threonine to methionine at codon 280
(T280M). The M280/I249 variant caused reduced function of the receptor, including decreased
adhesion, signaling and chemotaxis (McDermott et al., 2003). The M280/I249 variant is also
associated with reduced risk for atherosclerosis. Moreover, in aged CX3CR1-/- but not in aged
CX3CR1+/+ or young CX3CR1-/- there was in age-related accumulation of microglia that led to
retinal neurodegeneration in the CX3CR1-/- (Combadiere et al., 2007).
FKN/CX3CR1 signaling has been shown to be neuroprotective in a number of brain
injury models (Cardona et al., 2006). The neuroprotective role of CX3CR1 has recently been
questioned in a model of focal cerebral ischemia where CX3CR1-/- mice had a worse outcome
following the transient middle cerebral artery occlusion (MCAO) whereas, FKN-/- mice had
improved outcome following MCAO (Soriano et al., 2002; Denes et al., 2008). The results of this
study may not disprove the role of CX3CR1 in neuroprotection, but instead provide more
supporting evidence of the diverse role of microglia and macrophages. Following a short dramatic
neuronal insult, such as an MCAO, a more robust early immune response may be protective to
the insult. This is in comparison to a prolonged neurodegenerative condition such as AD or PD.
Moreover, as the blood brain barrier (BBB) is broken by the MCAO a different complement of
immune cells may be recruited to the injury compared to a neurodegenerative condition with an
intact BBB.
Microglia
Microglia are always surveying the microenvironment, and once they sense the
appropriate signals such as neuronal damage the cells will hone to the site of damage (Davalos
et al., 2005; Nimmerjahn et al., 2005). As the resident innate immune cells in the CNS, microglia
constitutively express surface receptors that trigger or amplify the innate immune response,
including toll-like receptors, complement receptors, cytokine receptors, chemokine receptors,
major histocompatibility complex (MHC) II, and others (Aloisi, 2001). The main cell type in the
6

CNS that is responsible for immunity is the microglia. Lipopolysaccharides (LPS) is an endotoxin
that is part of the outer membrane of gram-negative bacteria. LPS up-regulates the production of
IL-1β by microglia (Lee et al., 1993). Cytokines such as IL-1β, and TNF-α can also act in an
autocrine or paracrine manner to increase the production of IL-1β by microglia (Lee et al., 1993).
Astrocytes can also be stimulated by IL-1β, but not by LPS, to produce TNF-α and IL-6. However,
the production of cytokines by astrocytes is less than that of microglia (Lee et al., 1993).
Therefore, while astrocytes and neurons can make inflammatory mediators, the microglia are the
main source of inflammatory cytokines (Aloisi, 2001).
However, the role of microglia is not destructive. Upon detection of homeostatic
disturbance, microglia rapidly respond by inducing a protective immune response. The protective
immune response begins with a transient upregulation of inflammatory molecules, including
proinflammatory cytokines, such as TNF-α, IL-1, and IL-6 and IL-12 (Gao et al., 2002; Mantovani
et al., 2004). This is followed by a protective phase that is immunomodulatory and
neuroprotective. The protective phase includes neurotrophic factors such as brain-derived
neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and insulin-like
growth factor 1 (IGF-1) (Miwa et al., 1997; Batchelor et al., 1999; Nakajima and Kohsaka, 2004).
Thus, microglia remove cells damaged from acute injury and protect CNS functions.
Microglia are neither pro-neurogenic or anti-neurogenic but their influence on
neurogenesis is dependent on their activation state of either ‘classically’ activated or ‘alternatively’
activated (Battista et al., 2006; Butovsky et al., 2006b) (figure 1). Much like what has been
proposed for peripheral macrophages, microglia are very pleiotropic. Microglia, can become
‘classically’ activated as defined by the release of pro-inflammatory cytokines (e.g. TNF-α and IL1β) (Giulian et al., 1986; Griffin et al., 1989). Once in this ‘classically’ activated, pro-inflammatory
state, microglia are associated with further production of these pro-inflammatory cytokines, ROS,
chemokines, and matrix metalloproteases, resulting in cell death of invading cells and tissue
destruction, and type-I inflammation (Mantovani et al., 2007). A second type of microglia are
those that are activated by such things as IL-4 and TGFβ, and are called ‘alternatively’ activated
or in an ‘M2’ state (following the TH1/TH2 classification of T-helper cells) (Mantovani et al., 2007).
Compare to the ‘M1’ or ‘classically’ activated state, microglia in the ‘M2’ state can be protective
(Mantovani et al., 2004). When microglia are in this ‘M2’ state there is little release of proinflammatory cytokines and they are resistant to activation by agents such as LPS (Mantovani et
al., 2007). Alternatively activated macrophages promote extracellular matrix formation and
angiogenesis (Mantovani et al., 2007). A third type of microglia is one that becomes dysfunctional
with age. The senescent microglia are not able to respond appropriately to stimuli and may
exacerbate neuroinflammation (Schwartz et al., 2006a; Streit, 2006a). Isolated microglia from
aged mice have elevated basal expression of TNF-α, IL-1β, IL-6, and TGFβ1 (Sierra et al., 2007).
When stimulated the mice were stimulated with LPS, the isolated microglia from aged mice
7

produced more of the proinflammatory cytokines TNF-α, IL-1β, IL-6, then the young LPS
stimulated mice, but the LPS fold change in cytokine production in aged mice was equal to that in
young mice. Therefore, microglia from aged animals can respond to an inflammatory challenge
the same as young mice, but the baseline of cytokine expression is elevated (Sierra et al., 2007).
Age Related Alterations in Adaptive Immunity
There is also a decrease in immunological function in the periphery (Miller, 1996;
Goronzy and Weyand, 2005). It appears that the age of the T-cell when it first encounters an
antigen will determine if a memory response is achieved. For example, T-cells from aged rats
were able to maintain memory function acquired when they were young, but were not able to
acquire new memory formation; this was most likely due to a lack of proliferative ability (Haynes
et al., 2003). Furthermore, aged naïve CD4 T-cells could be stimulated by exogenous IL-2 to
induce memory, but once the IL-2 was removed the memory was lost (Haynes et al., 2003). Even
as most T-cell function declines with age, the CD4+CD25+ T regulatory (Treg) cells are still able to
suppress the activity of young CD4+CD25- T helper (Teff/Th) (Nishioka et al., 2006). Even more
important, the CD4+CD25- T-cells not only become unresponsive with age they also become
suppressive limiting the immune response (Shimizu and Moriizumi, 2003).
The CNS does have a reservoir to drain antigen in the cervical lymph nodes (Cserr and
Knopf, 1992). The recruitment of leukocytes can also take place in postcapillary venules (Hickey,
2001). It has been shown that there are changes to structure and function of the blood-brainbarrier (BBB) as a result of age, which causes an increase in permeability (Mooradian, 1988,
1994; Morita et al., 2005). Normally, in a young adult in the absence of disease, there is a clear
demarcation between the peripheral immune system, innate and adaptive, and the CNS immune
system with its ‘lone sentinel,’ the microglia.
Following an acute stimulation such as a traumatic injury or ischemia, the protective
status of the CNS is revoked and peripheral immune cells (dendritic cells and T-cells) can enter
into the CNS. The consequences of the invading peripheral immune cells are to either, clear
debris and rebuild damaged tissue or exacerbate the injury. T-cells can be involved in governing
the immune response (Kim et al., 2007). T-cell response may act by altering the activity of the
microglia and this response is important to maintain neurogenesis (Kipnis et al., 2004; Butovsky
et al., 2006a; Butovsky et al., 2006b; Schwartz et al., 2006a)
Injury is not the only time that this immune privilege is revoked, in aging you can also
find invasion of T-cells and dendritic cells (Stichel and Luebbert, 2007). Occurring as early as 12
months of age in rats, dendritic cells and T-cells can be found in the brain. These peripheral
immune cells, which are absent in young adult rats, are found widely distributed throughout the
aged rat brain, and are particularly associated with white matter tracks (Stichel and Luebbert, ;
Bulloch et al., 2008). What causes this invasion of peripheral immune cells is not entirely known.
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The increase of microglia presenting antigen, as shown by expression of major
histocompatibility complex Class II (MHC II), as well as, an increase in the peripheral immune
systems professional antigen presenting cells (dendritic cells) in the aged brain, may be a useless
response as the T-cells don’t appear able to respond to the antigen. The presentation of antigen
to T-cells by APCs is futile, as the T-cells do not appear able to respond to the antigen. The lack
of an immune response appears to lead to tolerance of T-cells and continued activation of APC,
and this futile response could be producing a positive feedback loop of chronic inflammation.
Human Umbilical Cord Blood Cells as a Potential Therapeutic
The mononuclear fraction of human umbilical cord blood (HUCB) contains a number of cell
types including, B-Cells, and T-Cells, monocytes, as well as, mesenchymal and endothelial
progenitor cells. HUCB is also a source of CD34+ hematopoietic stem cells (Bender et al., 1991;
Ho et al., 1996; Wu et al., 1999). HUCB cells, particularly the CD34+ stem cells, have in animal
models of stroke provided multiple benefits adding in the function recovery after the infarct (Chen
et al., 2001; Saporta et al., 2003; Willing et al., 2003; Taguchi et al., 2004; Vendrame et al., 2004;
Vendrame et al., 2005; Vendrame et al., 2006b) While HUCB CD34+ stem cell have the potential
to differentiate into neurons in vitro, when these cells are transplanted into the brain few survive.
Previously immunohistochemical analysis directed towards a human nuclear antigen (HuNu) has
found few HuNu positive cells surviving after the transplant and the small number of surviving
HUCB cells in the brain rules out a direct replacement of the lost cells as a mechanism for the
beneficial effects of HUCB cells (Chen et al., 2001; Vendrame et al., 2004). Taguchi et al. (2004)
showed that some of the functional recovery after stroke provided by CD34+ cells was due to
enhancement of both neurogenesis and angiogenesis (Taguchi et al., 2004). The article by
Taguchi et al. (2004) is concerned with the neurogenesis occurring post-stroke in regions of the
brain considered non-neurogenic (Taguchi et al., 2004).
The effects of HUCB seem to be due to a regulation of the microenvironment of the brain,
through releasing tropic factors or reducing inflammation and not by direct replacement of cells. It
was recently demonstrated that a systemic injection of HUCB cells could suppress inflammation
in the brain inflammatory response after stroke. Moreover, the effects of HUCB cells seemed to
shift the cytokine expression from a Th1 response to a Th2 response (Vendrame et al., 2004;
Vendrame et al., 2005; Vendrame et al., 2006b). Besides the immune modulatory effects, HUCB
cells also produce a number of trophic factors including but not limited to, vascular endothelial
growth factor, nerve growth factor, and cytokine colony stimulating factor-1, thrombopoietin, and
IL-11 (Suen et al., 1994; Taguchi et al., 2004; Vendrame et al., 2004).
Conclusion
Neurogenesis is an important means of neural plasticity that is diminished with increasing
age. Neurogenesis from endogenous NPC may provide an alternative to transplantation of stem
cells as a means to replace damaged neural tissue after brain injury, such as stroke, or as a
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result of a neurodegenerative condition. A growing body of research shows that neurogenesis
may occur in ‘non-neurogenic’ regions as a result of a stroke or neurodegenerative disease
(Kokaia and Lindvall, 2003). There is also the hope of recruiting neural stem cells, from the
neurogenic regions of the brain to replace damaged cells after injury (Bernal and Peterson,
2004). Before either strategy of using neurogenesis as a therapeutic source of new cell can be
implemented, a better understanding of the regulation of neurogenesis is necessary.
During aging and exacerbated in AD, a state of chronic inflammation occurs (Bodles and
Barger, 2004; Joseph et al., 2005; Mrak and Griffin, 2005). Inflammation, while not the only cause
for the decrease in neurogenesis with age, is very important in regulating neurogenesis (Ekdahl
et al., 2003; Monje et al., 2003). To harness the potential of neurogenesis to help in brain repair a
better understanding of the mechanism of how inflammation is regulating neurogenesis is
necessary. While a loss of trophic factors and increased corticosteroids are important contributors
to the aged niche and have been extensively reviewed (Drapeau and Nora Abrous, 2008) the
focus of following chapters of this dissertation are limited to the role of inflammation in regulating
stem cell function in the aged neurogenic niche.
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Fig.1. Microglia: protective or harmful? Microglia are normally in a resting state in which they
are actively surveying the microenvironment of the brain. The microglia are resting in the sense
that they are not performing effector functions such as producing inflammatory mediators like IL1β and TNFα. When microglia are producing inflammatory mediators the microglia would be
considered in a ‘classically activated state or ‘TH1’ state. Microglia can also become ‘alternatively
activated’ in such a way that they produce growth factors, such as IGF-1 and TGFβ. The
‘alternatively activated’ microglia can support tissue remodeling and repair. Beyond releasing
signaling molecules, microglia also have an important role in phagocytosis. The role of microglia,
as protective or harmful, depends upon the ability of the microglia to switch from the different
activation states at the appropriate time. Understanding how and when to turn microglia ‘on’ or
‘off’ is an important future direction of research. This is especially the case with aging where
microglia are most need for remodel and repair and to remove damaged cells and misfolded
proteins. With age microglia may lose the ability to perform these important effector functions
making the aged brain more susceptible to injury and insult.
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Blockade of Caspase-1 Increases Neurogenesis in the Aged Hippocampus
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Abstract
Adult hippocampal neurogenesis dramatically decreases with increasing age, and it has
been proposed that this decline contributes to age-related memory deficits. Central inflammation
contributes significantly to the decrease in neurogenesis associated with aging. Interleukin-1β is
a proinflammatory cytokine initially synthesized as an inactive precursor that is cleaved by
caspase-1 to generate the biologically active mature form. Whether IL-1β affects neurogenesis in
the aged hippocampus is unknown. Here we analyzed cells positive for 5`-bromo-deoxy-uridine
(BrdU, 50 mg/kg) in animals in which cleavage of IL-1β is inhibited by the caspase-1 inhibitor AcYVAD-CMK (10 pmol). Aged (22 mo) and young (4 mo) rats received Ac-YVAD-CMK for 28 d
intracerebroventricularly through a brain infusion cannula connected to an osmotic minipump.
Starting on day 14, animals received a daily injection of BrdU for 5 consecutive days. Unbiased
stereology analyses performed 10 d after the last injection of BrdU revealed that the total number
of newborn cells generated over a 5-d period was higher in young rats compared to aged rats. In
addition, there was a 53% increase in the number of BrdU-labeled cells of the aged Ac-YVADCMK- treated rats compared to aged controls. Immunofluorescence studies were performed to
identify the cellular phenotype of BrdU labeled cells. The increase in BrdU-positive cells was not
due to a change in the proportion of cells expressing neuronal or glial phenotypes in the
subgranular zone. These findings demonstrate that the intracerebroventricular administration of
Ac-YVAD-CMK reverses the decrease in hippocampal neurogenesis associated with aging.
Introduction
Neurogenesis occurs throughout life, predominantly in the subgranular zone (SGZ) of the
dentate gyrus in the hippocampal formation and in the subventricular zone (SVZ) (Altman and
Das, 1965b; Cameron et al., 1993; Eriksson et al., 1998; Gage, 2002; Lie et al., 2004; Mackowiak
et al., 2004; Christie and Cameron, 2006). Neural stem cells in the SGZ give rise to progenitor
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cells that migrate into the granule cell layer and differentiate into neuronal or glial phenotypes.
Newly generated hippocampal granule cells acquire the morphologic and biochemical properties
of neurons, develop synapses on their cell bodies and dendrites, and extend axonal projections
along mossy fibers into the hippocampal CA3 region (Hastings and Gould, 1999; Markakis and
Gage, 1999; Carlen et al., 2002). These newly generated granule neurons are electrically active,
fire action potentials, and receive synaptic input (Cameron and McKay, 2001; van Praag et al.,
2002; Schmidt-Hieber et al., 2004; Overstreet-Wadiche et al., 2006; Overstreet-Wadiche and
Westbrook, 2006) and survive for an extended period of time (Altman and Das, 1965b).
A multitude of factors have been shown to regulate the production of new neurons in the
adult hippocampus. For example, the rate of neurogenesis decreases with increasing age (Seki
and Arai, 1995; Kuhn et al., 1996; Lichtenwalner et al., 2001; Bizon and Gallagher, 2003).
Several lines of evidence suggest a correlation between adult neurogenesis and learning, and it
has been proposed that a decline in hippocampal neurogenesis contributes to a physiologic
decline in brain function (Gould et al., 1999b; Ambrogini et al., 2000; Kempermann and Gage,
2002; Bizon and Gallagher, 2003; Drapeau et al., 2003; Leuner et al., 2004; Bruel-Jungerman et
al., 2005). New and important insights as to the production of new neurons may affect
hippocampal-dependent memory ability have been provided by behavioral experiments
performed using the Morris water-maze task, which is a hippocampal-dependent memory task
used to analyze spatial memory. The learning performance in the water-maze task is
characterized by two consecutive phases: an early phase during which the learning performance
reaches 80% and a late phase during which the learning performance decreases to 20% after
which a stable baseline is reached. Importantly, it has recently been shown that spatial learning
in both young and aged rats increases the survival of cells generated before the learning (Gould
et al., 1999b)but decreases the survival of cells born during the early phase of learning (Lemaire
et al., 2000; Shors et al., 2001; Dobrossy et al., 2003; Drapeau et al., 2007). Thus, it seems that
the new born cells generated before training may be at the critical period of sensitivity to be
rescued by learning. On the other hand, cells generated during the early phase of learning may
be too young to be rescued.
In rats, numerous conditions that increase adult hippocampal neurogenesis are
associated with an increase in learning performance (Luine et al., 1994; de Quervain et al., 1998;
Bizon and Gallagher, 2003; Drapeau et al., 2003; Mirescu and Gould, 2006). For example,
decreases in glucocorticoid levels, which are elevated in aged rats, increases neurogenesis
(Gould et al., 1998) and spatial memory in the water-maze (Drapeau et al., 2003). Furthermore,
injection of N-methyl-D-aspartate receptor antagonists into aged rats significantly improves
memory deficits and increases neurogenesis (Cameron et al., 1995; Nacher et al., 2001; Nacher
et al., 2003; Nacher and McEwen, 2006; Nacher et al., 2007). Finally, insulin-like growth factor,
fibroblast- growth factor -2, and endothelial-growth factor decrease with aging, and administration
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of these trophic factors increases neurogenesis in the hippocampus (Beck et al., 1995; O'Kusky
et al., 2000; Cheng et al., 2001; Zaman and Shetty, 2002). Likewise, an enriched environment,
exercise , and caloric restriction or dietary supplementation with blueberries improve age-related
memory deficits and increase neurogenesis (Paylor et al., 1992; Kempermann et al., 1997b,
1998; van Praag et al., 1999; Kempermann et al., 2002; Casadesus et al., 2004; Olson et al.,
2006). These observations suggest that the age-related decrease in neurogenesis is due to a
global, age-related alteration in the microenvironment of the brain. Recent reports indicate that
brain inflammation negatively influences adult hippocampal neurogenesis (Ekdahl et al., 2003;
Monje et al., 2003). Intracortical infusion of lipopolysaccharides (LPS), a potent activator of the
inflammatory response, induces an 85% reduction in the number of new neurons in the dentate
gyrus SGZ (Ekdahl et al., 2003; Monje et al., 2003). Systemic administration of minocycline,
which inhibits microglial activation, restores LPS-induced decreases in neurogenesis. In addition,
tumor necrosis factor α (TNFα) is involved in the regulation of adult hippocampal neurogenesis
(Iosif et al., 2006). Interleukin-1 β (IL-1 β) is a proinflammatory cytokine involved in the
pathogenesis of several acute and chronic neurodegenerative diseases. There is extensive
evidence that IL-1β is constitutively expressed in the brain, synthesized by neuronal and/or glial
cells, and released in response to a variety of stimuli, including immune system activation
(Benveniste, 1992; Rothwell et al., 1997). High brain levels of IL-1β are also correlated with
natural aging and the development of cognitive dysfunction (Rachal Pugh et al., 2001; Lynch,
2002; Yirmiya et al., 2002). For example, contextual fear conditioning, a hippocampal-dependent
memory task, is impaired in aged rats, and administration of a nonsteroidal anti-inflammatory
drug, sulindac, reversed the impairment and decreased IL-1β levels (Mesches et al., 2004).
Almost every cell type is affected by IL-1β acting through its high - affinity receptor, IL-1RI
(Rothwell et al., 1997; Dinarello, 1998). Binding studies indicate that the hippocampus contains
the highest density of IL-1β binding sites (Farrar et al., 1987; Takao et al., 1990). Interleukin-1β is
synthesized as an inactive precursor that is cleaved by the protease caspase-1 to generate the
mature 17kDa form. Caspases are a family of proteases that have a critical role in apoptosis and
inflammation and are also implicated in cognition. The caspase family includes inflammatory
caspases (caspase-1, 4, 5, 11, and 12), initiator caspases (2, 8, 9, and 10), and executioner
caspases (caspase-3, 6, and 7). Caspase-1 (IL-1β converting enzyme) is constitutively
expressed in macrophages and microglia and is involved in the activation of both apoptosis and
inflammation through the production of IL-1β. Caspase-1 inhibition has shown extraordinary
promise in multiple disease models. For example, in cerebral ischemia, caspase-1 is
neuroprotective by reducing apoptosis and decreasing the production of proinflammatory
cytokines (Rabuffetti et al., 2000). Recently, we demonstrated that caspase-1 inhibition
significantly improves hippocampal-dependent contextual memory function by inhibiting IL-1β,
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TNFα, and caspase-3 activity in the hippocampus (Gould et al., 1999b). Here we demonstrate
that inhibition of caspase-1 activity increased hippocampal neurogenesis in the aged brain.
Material and Methods
Animals. All experiments were performed in accordance with the National Institutes of
Health Guide and Use of Laboratory Animals.
Surgical procedure and treatments. The study used male Fischer 344 rats (NIA
contract colony, Harlan Sprague Dawley, Indianapolis, IN). Rats were housed in pairs and
maintained in environmentally controlled chambers on a 12:12-h light-dark cycle at 21 ± 1 ºC.
Food and water were provided ad libitum. We used groups of 8 aged (20 mo) or 8 young (4 mo)
rats (4 subgroups = old caspase -1 inhibitor (Ac-YVAD-CMK), old controls, young Ac-YVAD-CMK,
young controls). The rats were implanted intracerebroventricularly (icv) with a brain infusion
cannula in the left lateral ventricle and an osmotic minipump (Alzet, Model 2004 pumping rate,
0.25 µl/h; total volume 200 μl) for 28 d. Before implantation, the pumps were incubated in sterile
saline for at least 48 h at 37°C to prime the pumps. For implantation, rats were anesthetized with
isofluorane and placed into a stereotaxic frame. A guide cannula was stereotaxically implanted in
the left ventricle (AP = -1.0 mm; ML = 1.6 mm, DV = -3.5) and connected to the osmotic
minipump, which was inserted subcutaneously. Pumps were weighed before implantation and at
the end of the experiment to ensure complete delivery of their content. The caspase-1 inhibitor,
Ac-YVAD-CMK (10 pmol/200 μl; Calbiochem, La Jolla, CA), was injected (0.25 μl/h) through the
cannula which was connected to the filled minipump. The infusion started the day of the surgery
and continued for 28 d. Control animals received the same volume of 0.6% DMSO (Sigma
Aldrich, St. Louis, MO) in saline. Rats received a daily injection of BrdU (Sigma; 50 mg/kg) once
a day for 5 d beginning on 14 d after surgery. Rats were sacrificed 10 d following the last
injection of BrdU (28d post-surgery). Rats were then perfused transcardially with saline followed
by 4% paraformaldehyde in PBS. The brains were removed and postfixed overnight and then
moved to 30% sucrose in PBS prior to sectioning on a cryostat.
BrdU staining procedure: Cryostat sections were cut in the sagittal plane (40μm),
collected in a cryoprotectant solution (30% ethylene glycol, 30% glycerol in 0.01 M PBS), and
stored at –20 ºC until processed. In preparation for an unbiased stereologic estimate of neuronal
numbers, an initial tissue section was selected randomly at one anatomic border of the brain
region to be examined. Thereafter, every 3rd section throughout the anatomic region of interest
was used for each staining series. For the immunohistochemistry staining procedure, selected
sections were floated individually in plastic multiwell carriers with nylon net bottoms. Free-floating
sections (40 µm) were pretreated with 50% formamide/2X SSC (0.3 M NaCl, 0.03 M sodium
citrate) at 65°C for 2 h, rinsed in 2X SSC, incubated in 2 N HCL for 30 min at 37°C, and washed
with borate buffer (pH 8.5). After washing with PBS three times, endogenous peroxidase activity
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was quenched by incubating in 0.3% H2O2 solution, followed by a 1- h incubation in blocking
solution (0.1 M PBS supplemented with 3% normal horse serum and 0.25% Triton X-100).
Sections were then incubated overnight with mouse-anti-rat-BrdU (1:50; Roche) in PBS
supplemented with 3% normal horse serum and 0.1% Triton X-100. Sections were washed and
biotinylated secondary antibody (1:200; Vector Laboratories, Burlingame, CA) in PBS
supplemented with 3% normal horse serum and 0.1% Triton X-100 was applied for 1 h. The
sections were incubated for 60 min in avidin-biotin substrate (ABC kit, Vector Laboratories). All
sections were incubated for 3 min in DAB solution (Vector Laboratories). Sections were mounted
onto glass slides and coverslipped with mounting medium.
OX-6 staining procedure: Immunohistochemistry was performed on every six section
throughout the dentate gyrus. Free-floating sections were processed individually for
immunoreactivity to the MHC Class II Ia antibody OX-6 in plastic 24-well plates (Corning, Inc.,
Corning, NY). Sections were rinsed in 0.1 M PBS, pH 7.4. Three 5-min washes were conducted
between steps except where indicated. Control sections not exposed to primary or secondary
antibodies were prepared simultaneously. After equilibrating tissue sections in washing solution,
endogenous peroxidase activity was quenched by incubating the sections in 0.1M PBS containing
0.3% H2O2 for 15 min. Background labeling was blocked by 1 h incubation in PBS containing
10% normal horse serum and 0.05% TX-100. Sections were then incubated overnight with
mouse-anti-rat- OX-6 (Pharmingen, San Diego, CA; 1:750) in PBS containing 3% horse serum
and 0.025% TX-100. After incubation in primary antibody, the sections were washed and
incubated for 60 min in biotinylated horse anti-mouse secondary antibody (Vector Laboratories,
Burlingame, CA; 1:300) diluted in washing solution containing 3% normal horse serum and 0.3%
TX-100. Sections were then incubated for 90 min in avidin-biotin “ABC Elite” substrate (Vector
Laboratories, Burlingame, CA). The sections were then rinsed three times for 10 min each in
PBS. Color development was performed in a standardized manner such that all sections were
developed in the same reagents for identical periods of time to allow for comparisons of fiber
staining intensity. All sections were incubated for 3 min in diaminobenzidine solution (Vector
Laboratories). Sections were mounted onto glass slides and cover - slipped with aqueous
mounting medium.
Stereology. BrdU cells were examined with a Nikon Eclipse 600 microscope and
quantified using Stereo Investigator software, Version 6 (MicroBrightField, Colchester, VT). Cells
were counted within two cell diameters below the SGZ using the optical fractionator method of
unbiased stereologic cell counting (West et al., 1991). The sampling was optimized to count at
least 250 cells per animal with error coefficients of less than 0.07. Each counting frame (75 x 75
μm) was placed at an intersection of the lines forming a virtual grid (100 x 100 μm), which was
randomly generated and placed by the software within the outlined structure.
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Stereologic estimation of the total number of OX-6 immunolabeled cells: The
dentate gyrus was outlined and analyzed. OX-6 positive cells in the dentate gyrus were counted
using the optical fractionator method of unbiased stereologic cell counting techniques. Optical
disectors were 100μm x 100μm. The sampling was optimized to sample at least 150 counted
cells per animal. Each counting frame was placed at an intersection of the lines forming a virtual
grid (200μm x 200 μm) that was randomly generated and randomly placed by the software within
the outlined structure. OX-6 - labeled cells were counted using a 60X oil lens (NA 1.4) and were
included in the measurement only when they came into focus within the disector (disector height
of 20 µm and the average thickness of mounted sections was 30 µm; thickness was measured at
random intervals throughout every section and estimated by the software program).
Immunofluorescence procedure: Immunofluorescence double labeling was performed
to determine the phenotype of BrdU positive cells. Tissues were pretreated with 2 N HCL for 2 h
at room temperature, washed, and incubated in blocking solution (0.1 M PBS containing 10%
goat serum and 0.3% Triton X-100) for 1 h at room temperature. Tissues were then incubated in
rat anti-BrdU (1:400; Accurate Chemical, Westbury, NY) overnight at 4°C. Tissues were rinsed
three times in PBS and goat anti-rat secondary antibody conjugated to Alexa 594 (1:800;
Molecular Probes, Eugene, OR) was applied for 1 h. Following 6 washes, one of the following
primary antibodies was applied overnight at 4°C: rabbit anti-GFAP (1:500; Dako, Carpinteria, CA),
mouse anti-NeuN (1:100; Chemicon, Temecula, CA), TuJ1 (1:800; Covance), rabbit cleaved
caspase -3 (1:100; Cell Signaling, Danvers MA). Tissues were washed three times with PBS and
species-appropriate secondary antibody conjugated to Alexa 488 (Molecular Probes) was applied
for 2 h at a 1:200 dilution (anti-GFAP secondary was applied for 1 h at a dilution of 1:800).
Following six washes in PBS, tissues were mounted on slides and coverslipped using Vectashield
(Vector Labs). To calculate the percentage of each phenotype with respect to the number of
BrdU-labeled cells, the total number of BrdU-labeled cells and their respective phenotypes for
each animal were scored in at least six or more sections of a one-in-six series. The results from
each section were summed, and the percentage for each marker was calculated. These
percentages were then expressed as the average of 4 to 6 animals. Colocalization of BrdUpositive cells with GFAP, TuJ1, NeuN, and caspase-3 was validated using a DMI6000 inverted
Leica TCS SP5 tandem scanning confocal microscope with a 63x/1.40NA oil immersion objective.
405 diode, 488 Argon and 546 laser lines were applied to excite the samples using AOBS line
switching to minimize crosstalk between fluorochrome. Images and Z-stacks were produced with
three cooled photomultiplier detectors and the LAS AF version 1.5.1.889 software suite.
Statistical analysis: Data are expressed as the mean ± standard error of the mean
(SEM). Analyses were performed using a two-way ANOVA followed by Fisher’s LSD post-hoc
analysis to identify significant effects. Differences were considered significant at *p ≤ 0.05; **p ≤
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0.001. A two tail unpaired t-test was performed to identify significant differences in the number of
0X-6 immunolabeled cells between aged treated and aged control rats.
Results
Chronic administration of Ac-YVAD-CMK increases the number of BrdU-postive
cells in the subgranule cell layer of the hippocampus. We previously demonstrated that
infusion of the caspase-1 inhibitor Ac-YVAD-CMK significantly ameliorates impairment of
hippocampal-dependent memory by decreasing caspase-1 and caspase-3 activity, as well as
protein levels of IL-1β and TNFα in the aged rat hippocampus compared to controls (Gemma et
al., 2005).The aim of the present study was to investigate whether the age-dependent increase in
hippocampal IL-1β affects the age-related decrease in hippocampal neurogenesis. The effects of
a 28 -d infusion of Ac-YVAD-CMK (10 pmol) on cell differentiation in the SGZ in young (4 mo) and
aged (20 mo) F344 rats was determined by analyzing 5’-bromo-deoxy-uridine (BrdU) staining 10
dafter the last BrdU injection. Figure 2 shows that BrdU - labeled cells in both young and aged
rats were primarily located on the border of the granule cell layer. Unbiased stereologic
quantification of total BrdU -labeled cells in the SGZ revealed that the number of newborn cells
generated over a period of 5 d was much higher in young than in aged rats. The results were
subjected to a 2 (age: young, aged) X 2 (treatment: saline, caspase-1 inhibitor) factorial ANOVA
(Fig. 3). There was a significant effect of age (F (1, 13) = 76.84, p < .001), but no significant
effect of treatment (F (1, 13) = 1.13, p = .306). Further, the age X treatment interaction was not
statistically significant (F (1, 13) = 2.37, p = .148). Although the interaction was not statistically
significant, the means clearly indicate that the response of the aged animals was different from
that of the young animals to caspase-1 inhibition. The lack of interaction was likely due to the fact
there was no treatment effect in the young animals and therefore the interaction itself was not that
strong. Despite the lack of a significant interaction, we compared the treatment effects for the
young and aged animals separately, but corrected for multiple comparisons because the original
interaction was not statistically significant. The results confirmed that there was no treatment
effect in the young animals (F (1, 6) = .06, P< = .822), but the effect in the aged group was
statistically significant (F (1, 7) = 19.13, P = .003). There was an increase of 53% in the number
of BrdU - labeled cells in the SGZ of aged rats compared to aged controls. This was a substantial
increase in neurogenesis, however, it was only 39% of the neurogenesis observed in young
control rats.
Determination of neuronal and glial phenotypes of BrdU - labeled cells in the
subgranule cell layer of the hippocampus. We then determined the phenotype of the newly
born cells using the neural nuclear protein NeuN and immature neural marker TuJ1. We found
that there was no difference in the proportion of BrdU – labeled cells expressing neuronal or glial
phenotype in the SGZ between aged treated and aged control rats (Fig. 4). Our analysis
18

revealed that 54% of BrdU - labeled cells in the aged control animals expressed NeuN, while the
percentage of BrdU/NeuN - positive cells in the aged treated rats increased to 73% (Tab. 1). The
immature neural marker TuJ1 was expressed in 43% of BrdU - labeled cells in aged treated rats
and 38% of cells in aged control rats. We then examined if there was a change in the glial
phenotypes. We found that very few BrdU-labeled cells were positive for glial fibrillary acidic
protein (GFAP; 4% control rats and 3% treated rats). Because BrdU is a marker of DNA
synthesis, there is a possibility that BrdU labeled cells are undergoing apoptotic cell death; thus,
to investigate this possibility, we double-labeled the BrdU cells with caspase-3. We found that
only 6.5% and 5% of BrdU positive cells expressed caspase-3 in the control and treated rats
respectively. When the percentage of each phenotype was summed, it revealed a number
greater than 100%, indicating that cells express more than one phenotype.
Ac-YVAD-CMK decrease microglia activation. Because IL-1β activates microglia and
activated microglia produce IL-1β, we explored whether the Ac-YVAD-CMK-induced increase in
neurogenesis was accompanied by changes in microglial activation. Microglia were identified by
OX-6 a marker for the major histocompatibility complex class II antigen expressed by activated
microglia. Stereological counting was performed on OX-6 - labeled cells expressed in the dentate
gyrus. The stereologic cell count of OX-6 - positive cells revealed that caspase-1 inhibition
caused a significant decrease in the number of OX-6 - positive cells in the aged treated dentate
gyrus compared to controls (Fig. 5; p<0.01). Interestingly, as shown in Figure 5B and 5C, a clear
morphological difference in the OX-6 positive cells phenotype was observed between treated and
non-treated animals. In the non-treated animals microglia were characterized by highly ramified
branching, indicating an activated state. In the treated animals, microglia were characterized by
long thin branches which indicate a more quiescent and resting state. We were unable to detect
enough OX-6 - positive cells in the hippocampus of young animals to perform a stereologic study.
Discussion
The present study explored whether the age-related increase in IL-1β contributes to the
decrease in hippocampal neurogenesis associated with aging. To examine this hypothesis, we
used the irreversible caspase-1 inhibitor Ac-YVAD-CMK to block caspase-1 activity, which is
known to be responsible for the production of the active mature form of IL-1β. Consistent with the
results of previous studies (Seki and Arai, 1995; Kuhn et al., 1996; Gould et al., 1998;
Lichtenwalner et al., 2001; Bizon and Gallagher, 2003), we show that neurogenesis is
dramatically reduced in aged animals. In addition, we provide new evidence that chronic
inhibition of caspase-1 activity increases the number of newborn cells in aged SGZ. The
percentage of the newly generated cells in the aged treated SGZ that differentiated into neural
phenotypes, such as NeuN and TuJ1, however, remains similar to that observed in aged control
animals. This finding is in agreement with previous data showing that newly born cells in the
aging dentate gyrus have a normal neuronal fate (Rao et al., 2006; Hattiangady and Shetty,
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2008). Whether the increase in neurogenesis observed in the present study is due to an increase
in cell proliferation or to protection and survival of the newly generated neurons cannot be
explained by the present data. Future studies looking at cell proliferation will help us to clarify this
point. Consistent with the detrimental role of inflammation on adult neurogenesis, Monje et al.
(2003) reported that systemic administration of LPS in adult female rats inhibits hippocampal cell
proliferation and this effect is completely blocked by the administration of a non-steroidal antiinflammatory drug.
Upregulation of IL-1β and activation of microglia occur during normal aging and
accompany many neurodegenerative diseases. Concomitant with an increase in neurogenesis in
aged treated rats, we observed a decrease in the number of activated microglia in the dentate
gyrus. A negative correlation between the degree of inflammation, indicated by the activation of
microglia, and the number of newborn neurons was previously reported (Ekdahl et al., 2003;
Monje et al., 2003). Thus, a decrease in microglial activation could also account for the
restorative effect of caspase-1 inhibition on neurogenesis. We observed a dramatic increase in
the number of BrdU - labeled cell in the SGZ of aged treated rats compared to controls. Even
with this substantial increase, however, neurogenesis remained substantially lower (39%) than in
young control rats. This finding raises the question of whether neurogenesis is functionally
important. Interesting, the same dose of Ac-YVAD -CMK completely reverses the impaired
cognition associated with aging (Gemma et al., 2005). Recently Rao et al (2006) demonstrated
that the largest decrease in hippocampal neurogenesis occurs between 7.5 months and 12
months of age, which corresponds to the period of adult-to-middle age, and there is a small
decline from 12 to 24 months of age (Rao et al., 2006). The authors suggest that there may be a
threshold of minimal levels of neurogenesis that occurs in the adult brain below which declines in
neurogenesis become detrimental, such as that observed at 24 months of age. If this hypothesis
is correct the increase in neurogenesis observed in this report, although not back to that observed
in very young animals, may be sufficient to cross above the threshold of minimal neurogenesis
allowing for proper function of the adult brain. In light of the results presented in this study, we
postulate that the increase in newborn neurons induced by caspase-1 inhibition might stimulate
endogenous mechanisms responsible for behavioral improvement.
Multiple mechanisms might underlie the effect of caspase-1 activity on hippocampal
neurogenesis in the aged brain. In a previous report, we have shown that the administration of
Ac-YVAD-CMK at the same dose used in the present study induced a 70% decrease of caspase1 activity and a 50% reduction of IL-1β protein in the hippocampus of aged rats (Gemma et al.,
2005). One possibility is that the increased number of newborn neurons observed here is due to
the inhibition of IL-1β. The effect of IL-1β most likely depends on several factors. For example,
IL-1β activation triggers a cascade of molecular events that culminates in the alteration of other
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proinflammatory cytokines, activation of prostaglandins, increases in glucocorticoids, and
activation of apoptosis. All these factors have been shown to decrease neurogenesis. Thus, we
cannot rule out the possibility that more than one mechanism is responsible for the beneficial
effects of caspase-1 inhibition on neurogenesis.
Caspase-1 is involved in the activation of both apoptosis and inflammation. One
important issue is whether the neuroprotective effects of caspase-1 inhibition on neurogenesis
proceed exclusively via a cytokine-dependent pathway or whether its involvement in apoptosis is
more critical. We previously demonstrated that the inhibition of caspase-1 decreases
hippocampal IL-1β levels and caspase-3 activity (Gemma et al., 2005). Whether the decrease in
caspase-3 activity is a downstream effect of IL-1β inhibition or whether caspase-1 directly
regulates caspase-3 activity cannot be determined in the present experiments. Thus, the
possibility that the neuroprotective effects of caspase-1 inhibition are a net consequence of a
decrease in apoptosis cannot be ruled out. However, the observation that caspase-1 knockout
mice develop normally, with no apparent physiologic or morphologic aberrations, however,
suggests that caspase-1 has no major role in programmed cell death during development.
Although the results presented here show a clear effect of the caspase-1 inhibitor Ac-YVAD-CMK
on hippocampal neurogenesis, it is important to point out that in the present study we did not
measure the hippocampal activity of caspase-1 or the hippocampal protein levels of IL-1β after
the administration of Ac-YVAD-CMK; thus, we can only assume that the administration of AcYVAD-CMK led to a decrease in the caspase-1 activity which led to a decrease in IL-1β protein
levels. Thus, additional effects of Ac-YVAD-CMK in the brain may be responsible for the increase
in hippocampal neurogenesis. Indeed, it has been shown Ac-YVAD-CM can exert
neuroprotective effects without affecting caspase-1 activity and IL-1β levels. For example, the
administration of Ac-YVAD-CMK counteract the gp-120-induced cytosolic cytochrome c elevation
without affecting IL-1β levels (Corasaniti et al., 2005). Furthermore, Ac-YVAD-CMK has been
shown to protect against oxygen and glucose deprivation-induced cell death in organotypic
cultures of rat hippocampal slices independently from IL-1β inhibition (Ray et al., 2000). In
conclusion, the findings in the present study demonstrated that the chronic intracerebroventricular
administration of Ac-YVAD-CMK reverses the age-dependent decrease in hippocampal
neurogenesis. Further studies need to be conducted in order to investigate in more detail the
molecular and cellular mechanism underlying the effect of Ac-YVAD-CMK on hippocampal
neurogenesis in the age rats.
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Table 1: To calculate the percentage of each phenotype with respect to the number of
BrdU-labeled cells, the total number of BrdU - labeled cells and their respective phenotypes were
scored in six or more sections of a one-in six series were scored. The percentages were then
expressed as an average of 4 to 6 animals.
* Expressed as percentage of BrdU
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Figure 2. Inflammation decreases basal hippocampal neurogenesis.
Immunohistochemical staining for BrdU - positive cells (20X) in the dentate gyrus after 28 d
intracerebroventricular infusion of vehicle or Ac-YVAD-CMK in young control rats and aged rats.
A. Young control rats; B. Aged control rats; C. Aged treated rats. BrdU was injected
intraperitoneally once a day for 5 consecutive days, and the rats were killed 10 d after the last
injection of BrdU. Note the presence of BrdU - immunoreactive nuclei located in the subgranular
zone. The number of BrdU-positive cells was dramatically lower in aged rats.
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Figure 3. Inhibition of caspase-1 attenuates the decrease in hippocampal
neurogenesis associated with aging. Stereologic quantification using an optical fractionator of
BrdU-positive cells in young and aged rats following 28 d intracerebroventricular infusion of
vehicle or Ac-YVAD-CMK. The results were subjected to a 2 (age: young, old) X 2 (treatment:
saline, caspase-1 inhibitor) factorial ANOVA. The results indicate a significant effect of age (F (1,
13) = 76.84, p < .001), but no significant effect of treatment (F (1, 13) = 1.13, p = .306). Further,
the age X treatment interaction was not statistically significant (F (1, 13) = 2.37, p = .148).
Multiple comparison of Ac-YVAD-CMK effect for the young and aged rats revealed that there was
no treatment effect in the young animals (F (1, 6) = .06, p = .822), but the effect in the old group
was statistically significant (F (1, 7) = 19.13, p = .003).
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Figure 4. Representative confocal micrograph of BrdU-labeled newborn cells
(BrdU, red) and their respective phenotypes (green) in the subgranular zone.
A, B and C. Overview of GFAP, NeuN and TuJ1 expression in the SGZ. D and E. Single
confonfocal plane of the same cell, showing co-localization of NeuN+ (green), BrdU+ (red) and
BrdU+/NeuN+ (orange) cells and TUJ1+ (green), BrdU+ (red) and BrdU+/TuJ1+ (orange), in the
SGZ of Ac-YVAD-CMK treated rats. Newly formed double-labeled neurons are visualized by
using confocal microscopy in an orthogonal projection composed of 25 optical z-planes (0.5mm
thick).
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Figure 5. Inhibition of caspase-1 significantly reduced microglia activation. A
Stereologic quantification using an optical fractionator of the number of OX-6 - positive cells in the
dentate gyrus of aged control and aged AC-YDAV-CMK treated rats. B and C are representative
photomicrograph of OX-6 positive staining (10X) in the dentate gyrus of aged control rats (B) and
AC-YVAD-CMK treated rats (C). Note the morphological difference of OX-6 positive cells
between treated and non treated animals.
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Abstract
Neurogenesis continues to occur throughout life but dramatically decreases with
increasing age. This decrease is mostly related to a decline in proliferative activity as a result of
an impoverishment of the microenvironment of the aged brain, including a reduction in trophic
factors and increased inflammation. We determined that human umbilical cord blood
mononuclear cells (UCBMC) given peripherally, by an intravenous injection, could rejuvenate the
proliferative activity of the aged neural stem/progenitor cells. This increase in proliferation lasted
for at least 15 days after the delivery of the UCBMC. Along with the increase in proliferation
following UCBMC treatment, an increase in neurogenesis was also found in the aged animals.
The increase in neurogenesis as a result of UCBMC treatment seemed to be due to a decrease
in inflammation, as a decrease in the number of activated microglia was found and this decrease
correlated with the increase in neurogenesis. The results demonstrate that a single intravenous
injection of UCBMC in aged rats can significantly improve the microenvironment of the aged
hippocampus and rejuvenate the aged neural stem/progenitor cells. Our results raise the
possibility of a peripherally administered cell therapy as an effective approach to improve the
microenvironment of the aged brain.
Introduction
Aging is accompanied by a process of cellular senescence that occurs throughout the
body, resulting in a decrease in the regenerative potential of the stem cell pools (Collado et al.,
2007). In the brain there are two stem cell pools, one residing in the subventricular zone (SVZ),
and the other in the subgranular zone (SGZ) of the dentate gyrus of the hippocampus. As in other
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stem cell pools such as the hemapoietic pool in the bone marrow or the satellite stem cells in the
muscle, the stem cells in the brain lose there capacity to generate new cells with age (Kuhn et al.,
1996; Cameron and McKay, 1999; Kronenberg et al., 2006b). In the brain it appears that the
decrease in neurogenesis is a result of a decrease in proliferation of the stem cells and not due to
a loss of the cells (Hattiangady and Shetty, 2006). In the muscle it has been shown that the stem
cells can be rejuvenated by exposure of the cells to the systemic environment of a young animal
through parabiosis (Conboy et al., 2005). Even though it has been known since the 1960s that a
cellular senescence occurs with age (Hayflick and Moorhead, 1961), it is less clear if this cellular
senescence leads to an aging phenotype, particularly to the age related cognitive decline.
However, it is clear that the process of cellular senescence that occurs with age is an
important mechanism to protect against cancer. There are a number of tumor-supressor genes,
including p53 and p16ink4A , which respond to cellular stressors to induce senescence (Campisi,
2005). It has recently been shown that knocking out p16ink4A can restore the proliferative potential
of the aged neural stem cells (Molofsky et al., 2006), but the animals have decreased longevity
due to tumor formation (Beausejour and Campisi, 2006). This demonstrates the important
balance that oncogenes play in protecting organisms from cancer, but with the negative
consequence of inducing an aging state of cellular senescence. An effective target to lessen the
amount of senescence might be the cellular stressors that accumulate with age which include
telomere shorting (Collado et al., 2007), oxidative stress (Harman, 1956; Ames and Shigenaga,
1992; Ames et al., 1993), inflammation (Blalock et al., 2003), increased corticosteroid levels
(Sapolsky, 1992), and a decrease in a number of trophic factors including brain-derived
neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), Insulin-like Growth
Factor-1 (IGF-1) and fibroblast growth factor 2 (FGF-2) (Hattiangady et al., 2005; Shetty et al.,
2005).
A potent cellular stressor that is increased with age is inflammation. Recently, our
laboratory has shown that reducing neuroinflammation in aged rats by blocking the conversion of
pro-IL-1β to IL-1β through inhibition of the converting enzyme caspase-1 rescued some of the
age-related decrease in neurogenesis (Gemma et al., 2007a) and resulted in an improvement in
cognitive function (Gemma et al., 2005). We believed that human umbilical cord blood
mononuclear cells (UCBMC) may have a similar potential to restore some of the loss in capacity
of the neural stem/progenitor cells ability to proliferate and differentiate into neurons.
In an animal model of stroke, UCBMC administered intravenously have reduced infarct
volume and improved functional recovery on behavioral measures (Vendrame et al., 2004). The
effects of UCBMC have been attributed to changes in the microenvironment of the brain, through
the release of trophic factors or by reducing inflammation, and not by a direct replacement of cells
(Borlongan et al., 2004; Vendrame et al., 2005; Newman et al., 2006). UCBMC contains a
number of cell types including B-Cells and T-Cells, as well as, mesenchymal and endothelial
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progenitor cells. UCBMC is also a rich source of CD34+ hematopoietic stem cells (Bender et al.,
1991; Ho et al., 1996; Wu et al., 1999). It was recently demonstrated that a systemic injection of
UCBMC cells could suppress inflammation in the brain following stroke. Moreover, the effects of
UCBMC cells seemed to shift the cytokine expression from a Th1 response to a Th2 response
(Vendrame et al., 2004; Vendrame et al., 2005; Vendrame et al., 2006a). In addition to the
immune modulatory effects, UCBMC cells also produce a number of trophic factors including, but
not limited to, VEGF, nerve growth factor, and cytokine colony stimulating factor-1,
thrombopoietin, and IL11 (Suen et al., 1994; Taguchi et al., 2004; Vendrame et al., 2004).
The goal of the present study was to determine if UCBMC could stimulate the
endogenous stem/progenitor cells to regenerate new cells. To this end, young and aged rats
were intravenously administered a single dose of UCBMC to determine if UCBMC could increase
proliferation of the neural stem/progenitor cells as well as to determine if there would be an effect
on neurogenesis in the aged rats. This study provides insight into how the aged stem cell niche
could be rejuvenated. Furthermore, as the UCBMC are administered minimally invasively this
study raises the possibility of a clinically applicable therapeutic for the aged brain.
Material and Methods
Cell preparation: Cryopreserved human umbilical cord blood mononuclear cells
(UCBMCs) were obtained from Saneron CCEL Therapeutics, Inc. (Tampa, FL, USA).
Cryopreserved Human peripheral blood cells (PBMC) (mononuclear fraction) were obtained from
AllCells, LLC (Emeryville, CA, USA). Just prior to intravenous (i.v.) injection, the UCBMC or
PBMC were thawed into media (Hanks' balanced salt solution, HBSS, Gibco) at 37°C, washed,
and the number of viable cells was determined using the trypan blue exclusion method
(Vendrame et al., 2005). Cell viability ranged from 85 to 88%. Cell concentration was adjusted to
106 viable cells/500μl. Rats were then anesthetized with 3% isofluorane and randomly chosen to
receive a single i.v. injection via the penile vein of UCBMC at a dose 106 cells shown most
effective in a stroke model (Newman et al., 2006), 106 PBMC, or media for both the aged and
young rats.
Animals: All experiments were conducted in accordance with the National Institute of
Health Guide and Use of Laboratory Animals, and were approved by the Institutional Animal Care
and Use committee of the University of South Florida, College of Medicine. Male Fisher 344
(F344) rats (NIA contract colony, Harlan Sprague Dawley, Indianapolis, IN), were pair-housed in
environmentally controlled conditions (12:12h light:dark cycle at 21±1°C) and provided food and
water ad lib. Two age groups of animals young (3 months old) and aged (20 months old) were
used in this study. The mean life span of the F344 rats is approximately 29 months with a
maximal life span of 36 months (Coleman et al., 1977).
Rats were then divided in three groups. Group 1 received 50 mg/kg of bromodeoxyuridine (5bromo-2-deoxyuridine, BrdU; Sigma, St. Louis, MO, USA), intraperitoneal (i.p.) twice a day
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beginning 24 hours the injection of UCBMC, and were sacrificed the subsequent day. Rats in
group 2 received BrdU (50 mg/kg, i.p.) twice a day, beginning fourteen days after the
administration of UCBMC and were sacrificed on the following day. Rats in Group 3 received
BrdU (50 mg/kg, i.p.) for five consecutive days, beginning the day after the administration of
UCBMC and were the sacrificed day fifteen.
Tissue collection and processing: The rats were anesthetized with pentobarbital (50
mg/kg, i.p.). Blood was collected by cardiac puncture and smears were made of the blood to look
for the presence of the transplanted cells. The rats were transcardiac perfusion with phosphatebuffered (PB), followed by 4% paraformaldehyde in PB. The brains were postfixed in 4%
paraformaldehyde for 12 h, after which they were transferred into 30% sucrose in phosphatebuffered saline (PBS) for at least 16 h, and stored at 4°C. Exhaustive caudal sections of the left
hemisphere were made, at 40μm using a Microm cryostat (Richard-Allan Scientific, Kalamazoo
Michigan) and stored in cryoprotectant at 4°C.
BrdU Immunohistochemistry: All immunohistochemical staining was conducted on
free-floating sections for every sixth section for the entire hippocampus beginning with a random
start and including sections before and after the hippocampus to ensure that the entire structure
was sampled; with one exception, in the aged animals from group 3 a one in three series was
stained to allow for sampling of an adequate number of BrdU+ cells. For BrdU staining, sections
were pretreated with 50% formamide/2X SSC (0.3 M NaCl, 0.03M sodium citrate) at 65°C for 2
hours, rinsed in 2X SSC, incubated in 2N HCL for 30 minutes at 37°C, washed with borate buffer
(pH 8.5), then PBS. This was followed by quenching endogenous peroxidase activity in 0.3%
H2O2 solution in 30% methanol; then one hour in blocking solution (0.1M PBS supplemented with
3% normal horse serum and 0.25% Triton X-100: PBS-TS); followed by incubation overnight with
mouse-anti-rat-BrdU (1:100; Roche) in PBS-TS. The following day the sections were washed and
then incubated for one hour in a biotinylated secondary antibody (1:200; Vector Laboratories,
Burlingame, CA) in PBS-TS; then washed before one hour incubation in avidin-biotin substrate
(ABC kit, Vector Laboratories, Burlingame, CA); and then washed before 10 minutes incubation in
DAB solution (Vector Laboratories, Burlingame, CA). Sections were then mounted onto glass
slides and coverslipped with mounting medium.
Doublecortin and OX-6 Immunohistochemistry: Doublecortin (DCX) is a marker of
migrating neurons that is expressed for approximately three weeks after the cell is born and has
been shown to be a reliable indicator of neurogenesis (Rao and Shetty, 2004; Couillard-Despres
et al., 2005). For DCX immunohistochemistry a polyclonal goat antibody raised against human
DCX (1:200; SC-8066, Santa Cruz biotechnology, Santa Cruz, CA, USA) was used following a
similar protocol to BrdU except the antigen retrieval steps were omitted and Goat serum (Vector
Laboratories, Burlingame, CA) was used instead of horse serum. For OX-6
immunohistochemistry a monoclonal antibody directed against the rat major histocompatibility II
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(MHCII) (RT1B, Becton, Dickinson Pharmingen, San Diego, CA, USA) was used at a
concentration of 1:750 in place of the other primary antibodies all other steps were the same.
Immunofluorescence: Tissues were pretreated with 2N HCL for 2 hours at room
temperature, washed, and incubated in blocking solution (0.1M PBS containing 10% goat serum
and 0.3% Triton X-100) for 1 hour at room temperature. Tissues were then incubated in rat antiBrdU (1:400; Accurate Chemical, Westbury, NY) and additional primary antibodies [anti-GFAP
(1:500; Dako, Carpinteria, CA), mouse anti-NeuN (1:100; Chemicon, Temecula, CA), mouse antiTUJ1 (1:800; Convance, Berkeley, CA)], overnight at 4°C. Tissues were then rinsed 3 times in
PBS and the appropriate secondary antibody conjugated to an Alexafluor probe (Molecular
Probes, Eugene, OR) was applied for 2 hour. Following 6 washes in PBS, tissues were mounted
on slides and coverslipped using Vectashield (Vector Labs, Burlingame, CA).
Human Nuclei immunofluorescence: To detect for the presence of the transplanted
cells, blood smears and tissue sections were stained with a mouse monoclonal antibody that
recognizes Human Nuclei antigen (HuNu) (MAB 1281; 1:50; Chemicon, Temecula, CA ), and
does not react with rat nuclei. Prior to incubation overnight at 4°C in the HuNu antibody, the
samples were washed in PBS and incubated in blocking solution (0.1M PBS containing 10% goat
serum and 0.3% Triton X-100) for 1 hour at room temperature. The HuNu antibody was visualized
by secondary antibody conjugated to an Alexafluor probe (Molecular Probes, Eugene, OR).
Quantification and imaging: To determine cell numbers the optical fractionator method
of unbiased stereological cell counting techniques (West et al., 1991) was used with a Nikon
Eclipse 600 microscope and quantified using Stereo Investigator software (MicroBrightField,
Colchester, VT). For the proliferation study, because of the low number of BrdU+ cell in the aged
animals the virtual grid and counting frame were both 125μm x 125μm in order to count all the
cells that were present in the section. For all other counts sampling was optimized to count at
least 200 cells per animal with error coefficients less than 0.07. Outlines of the anatomical
structures were done using a 10x/0.45 objective and cell quantification was conducted using a
60x/1.40 objective. OX-6+ cells were counted in the entire dentate gyrus including the subgranular
zone (SGZ: defined as a two cell diameter band on both sides of the granular cell layer (GCL)).
All other cell counts were done in the SGZ/GCL. The phenotype of the BrdU+ cells were analyzed
using an inverted Zeiss LSM 510 confocal microscope with a 40x/1.30NA oil immersion objective.
Argon and HeNe laser lines in conjunction with 488 and 555 band pass filters were applied to
excite the samples using line switching to minimize crosstalk between fluorochromes. Images
and Z-stacks were produced with dual photomultiplier detectors and the LSM 5 version 3,2,0,115
software suite, and optical Z stacks where created at 2μm intervals throughout the 40μm of the
sections with a guard region of 2μm excluded from top and bottom of the Z stack. The Z stacks
were rotated in all planes to verify double labeling.
31

Statistical analyses: Data are presented as mean cell number ± SEM. Statistical
analysis was performed using an unpaired, two-side t-test, or a one-way ANOVA followed by a
Tukeys post-hoc test. p<0.05 was considered to be significant.
Results
Human umbilical cord blood mononuclear cells (UCBMC) stimulate proliferation of
the senescent hippocampal neural stem cell. In the first of a series of experiments we wanted
to determine if UCBMC given intravenously could stimulate the proliferation of the endogenous
stem/progenitor cells in the hippocampus. We chose to study proliferation as a slowing of the cell
cycle and a decrease in proliferation seems to be most affected with age when compared to the
ability of the cells to survive and differentiate into neurons which appears to occur at relatively the
same rate in young animals (Rao et al., 2005). The effect of a single intravenous injection of
UCBMC on cell proliferation in the granule cell layer in young (3-months old ) or aged (20-months
old) F344 rats was determined by analyzing BrdU staining 24 hours after the BrdU injections (48
hours following UCBMC injection). Using the optical fractionator method of design based
stereology (West et al., 1991), we found that in the aged animals there was a significant increase
(t(9)= 4.256; p < 0.005) in the number of BrdU+ cells in the UCBMC group (2504 ± 227.3 n=5)
compared to the animals that received media alone (1549 ± 82.07 n=6) (Figure 6A). In young
animals there was no significant effect of the UCBMC treatment (data not shown). To determine if
there might be a prolonged effect on proliferation in the aged F344 rats BrdU injections were
given 14 days after the UCBMC treatment. Figure (6E) shows the effect of a single intravenous
injection of UCBMC on the number of cells that incorporated BrdU on day 14. Stereological
analysis revealed that in the aged UCBMC-treated rats there was a significant increase in the
number of BrdU+ cells (t(12)= 3.468; p < 0.01) (2357 ± 149.4 n=6) compared to the media-treated
group (1548 ± 176.9 n=4).
Neurogenesis is stimulated in the aged hippocampus following UCBMC treatment.
To determine if UCBMC would also stimulate neurogenesis in the aged rats, doublecortin (DCX)
immunostaining was examined. Counting the number of DCX+ cells in the SGZ/GCL, we found a
significant increase (t(16)= 2.188; p < 0.05) in the number of DCX+ cells in the aged rats 15 days
after a single i.v. injection of the UCBMC (2619 ± 212.6 n=9) compared to animals that received
media alone (1843 ± 283.9 n=9) (Figure 7A). To confirm the results obtained by DCX, and to
determine if there was any change in the ability of the proliferating cells to differentiate following a
UCBMC treatment, we injected the animals with BrdU (50mg/kg) for five days beginning 24 hours
after our i.v. treatment. Quantifying the number of BrdU+ cells in the SGZ/GCL using the optical
fractionator method of design based stereology we found a similar increase in the number of
BrdU+ cells in the aged UCBMC treated group as was found using the neurogenic marker DCX
(Figure 7A-D). In aged rats, there was a significant increase (F(2, 14) = 10.94, p < 0.005) in the
number of BrdU+ cells generated over a period of five days following a single i.v. injection of
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UCBMC (2772 ± 263.3 n=5) compared to the rats that received media alone (1498 ± 206.1 n=5);
as determined by the Tukey’s Multiple Comparison Test (p<0.01). In this experiment, we also
included a group that was injected with adult human peripheral blood mononuclear cells (PBMC)
as a control for the effect of delivering cells. The PBMC group was determined to have
significantly fewer BrdU+ cells (1712 ± 171.2 n=5) than the UCBMC treated group (p<0.01), but
this was not significantly different from the group that received media alone (Figure 7E-H). As
with the results of the proliferation study, young rats showed no significant effect of UCBMC
treatment (data not shown). To determine if the treatment with UCBMC might alter the phenotype
of the newborn cells, we double labeled with the antibodies to Tuj1, NeuN and GFAP. While
exhaustive sampling was not conducted, 50 BrdU+ cells were analyzed from each rat (4 rats per
group) using confocal microscopy for each marker and there did not appear to be any change in
phenotype due to the treatment (Figure 7I-J). To confirm that the increase in neurogenesis was
from the endogenous stem/progenitor cells, sections were stained for HuNu to look for the
presence of the transplanted cells in the brain. Cells positive for the HuNu were found in the
blood smears of the rats that were treated with UCBMC, but no HuNu immunoreactive cells were
found in the hippocampus of the rats (data not shown).
A decrease in microglia activation following UCBMC correlates with the increase in
neurogenesis. Using the optical fractionator method of design based stereology, we counted the
number of OX-6+ cells in the dentate gyrus 15 days after a single UCBMC injection; this was at
the same time point that we observed an increase in DCX+ cells and BrdU+ cells. OX-6 is a
marker for MHCII and presumably stains for microglia in an activated, proinflammatory state. In
aged rats, we found that 15 days after the UCBMC treatment there was a significant decrease
(t(12)= 2.699; p < 0.05) in the total number of activated OX-6+ microglia in the UCBMC group
(678.7 ± 155.3 n=7) compared to the media control (1217 ± 128.0 n=8) (Figure 8A). The
decrease in OX-6+ microglia negatively correlated with the number of DCX+ cells (Spearman
r(15)= -- 0.6429; p<0.01) (Figure 3E).
Morphologically the OX-6+ cells expressed two main phenotypes (see Figure 8F). Type 1
microglia appear to be in a more quiescent state based on morphology Type 2 microglia were
thought to represent a more activated state. The type 1 microglia make up the majority of the OX6+ cells in the dentate gyrus and were found to be significantly decreased (unpaired t(12)= 2.791;
p < 0.05) in aged rats following UCBMC treatment (426.6 ± 117.0 n=7) compared to controls
(842.4 ± 94.67 n=8) (Figure 8G). The type 2 microglia, while representing a smaller percentage of
the total OX-6+ microglia, were significantly reduced (t(12)= 3.281; p < 0.01) to a greater extent by
the UCBMC treatment (53.30 ± 13.27 n=7) compared to controls (212.9 ± 43.82 n=8) than the
total microglia (Figure 8H). Fifteen days after the UCBMC treatment, there was a 4 fold change in
the number of type 2 OX-6+ microglia, whereas there was only a 1.8 fold change in the total
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number of OX-6+ microglia. It appears that the highly activated microglia are being reduced to a
greater extent by the UCBMC treatment, although all OX-6+ microglia are affected.
Discussion
The present study explored whether human umbilical cord blood mononuclear cells
(UCBMC) could improve the neurogenic niche of the aged brain and stimulate the endogenous
stem/progenitor cells to generate new neurons. As determined by stereological analysis of both
DCX and BrdU, a single peripherally administered injection of UCBMC appeared to stimulate
neurogenesis. The finding that the administration of UCBMC also increased the number of
proliferative cells generated within 24 hours following the treatment, suggests that the increase in
neurogenesis observed in this study may be a consequence of an increase in proliferation rather
than changes in differentiation or survival of newly generated cells. To support this hypothesis, it
will be important to allow more time for the cells to fully mature and then determine if there is still
no change in the phenotype of the BrdU+ cells. It will also be important to determine what effect
UCBMC have on the survival of the BrdU+ cells.
In addition, it was determined that UCBMC were able to increase cell proliferation for at
least fifteen days in the aged rats. This suggests that the UCBMC may have a beneficial effect on
the microenvironment of the aged brain. In support of this hypothesis we show that coinciding
with an increase in neurogenesis in the aged treated rats, there was a decrease in the number of
activated microglia in the dentate gyrus. A negative correlation between the degree of
inflammation as indicated by the activation of microglia and the number of newborn neurons has
been previously described (Ekdahl et al., 2003). Consistent with previous studies showing that
UCBMC have the potential to reduce neuroinflammation (Vendrame et al., 2004; Rao et al., 2005;
Vendrame et al., 2005; Vendrame et al., 2006a) in the aged brain, we did find that neurogenesis
correlated with the number of activated microglia, suggesting that UCBMC were stimulating
neurogenesis by decreasing microglia activation. Although other possibilities cannot be excluded,
since UCBMC could be having multiple effects including increasing trophic support as previously
published (Suen et al., 1994; Taguchi et al., 2004; Vendrame et al., 2004).
UCBMC have been shown to reduce neuroinflammation (Vendrame et al., 2004; Rao et
al., 2005; Vendrame et al., 2005; Vendrame et al., 2006a) and, consistent with previous studies,
we show here that the peripherally administered UCBMC do have anti-inflammatory properties. It
appears that one of the factors that leads to the negative regulation of neural stem cells is
inflammation (Ekdahl et al., 2003; Monje et al., 2003; Battista et al., 2006). A primary source of
inflammation in the CNS is from the macrophages/microglia which can produce a wide array of
cytotoxic factors, including proinflammatory cytokines such as tumor necrosis factor (TNF), IL-1,
IL-6 and IL-12 (Gao et al., 2002; Mantovani et al., 2004). With age, microglia shift from a
quiescent state into an active proinflammatory state. It is not clear if this change in activation state
is in response to injury, infection, or debris or if it is due to dysregulated cytokine levels. Another
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possibility recently proposed, is that microglia becoming senescent and this leads to them
becoming dysfunctional (Schwartz et al., 2006b; Streit, 2006b). It has previously been
demonstrated in models of induced inflammation through the use of LPS or radiation, a dramatic
decrease in proliferation and neurogenesis occur, and when the inflammation is alleviated the
replicative potential of the stem cells returns (Ekdahl et al., 2003; Monje et al., 2003). This effect
is likely a protective mechanism so that the DNA is not exposed to the noxious inflammatory
environment which could damage the replicating DNA. This correlation also imparts support to
the hypothesis that UCBMC stimulate neurogenesis by decreasing inflammation, particularly the
activation state of microglia. However, it does not rule out the possibility that UCBMC may be
acting on multiple targets, with microglia only representing one part of the total mechanism.
While UCBMC do seem to have an effect on microglia, it is not clear how this occurs. A
number of studies have shown that T-cells appear to act on macrophages/microglia to cause
them to adopt a phenotype that is ‘pro-repair’ (i.e. the macrophages/microglia: clear debris, buffer
toxic compounds, and produce growth factors), without being pro-inflammatory (i.e. producing
TNF-α, NO, or COX-2) and this effect can promote neurogenesis and be neuroprotective (Shaked
et al., 2004; Butovsky et al., 2006c; Ziv et al., 2006a; Ziv et al., 2006b; Ziv et al., 2007). As T-cells
are a major fraction of UCBMC, it is possible that the naïve T-cells in the UCBMC are able to
induce a protective T-cell mediated response in the aged rats, since adult PBMC did not have an
effect. Alternatively, the CD34+ stem cells in the UCBMC may be involved. Taguchi et al.
(Taguchi et al., 2004) has shown that CD34+ stem cells can increase both angiogenesis and
neurogenesis as part of the protective mechanism against stroke. From the results of the current
study it can not be determined if the effects of the UCBMC are a result of direct action on the
brain or though peripheral effect. However, the fact that we did not detect any immunoreactivity
for human nuclei in the brains of the UCBMC-treated rats raises the possibility that the UCBMC
may be acting through a peripheral mechanism. Moreover, the observation that the adult PBMC
did not alter hippocampal neurogenesis ruled out the possibility of a non-specific effect due to an
influx of cells, supporting our belief that the increase in neurogenesis, which occurred following
treatment with UCBMC was not due to an influx of cells but was specific to UCBMC.
The present study did not attempt to determine if decreasing senescence of the neural
stem cells could reverse the cognitive decline with age. There is still much debate surrounding
the role of neurogenesis in learning and memory (Gould et al., 1999a; Shors et al., 2001; Shors et
al., 2002; Merrill et al., 2003; Leuner et al., 2006; Kee et al., 2007) and whether cellular
senescence of the stem cell pool with age leads to an aging phenotype. While not a goal of the
current study, it will be important to determine if the rejuvenation of the aged stem/progenitor cell
pool can reverse the age-related cognitive decline.
In summary, this study demonstrates that a single peripheral injection of UCBMC could
stimulate the endogenous neural stem/progenitor cells to increase proliferation. We also
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determined that the UCBMC were able to improve the microenvironment of the aged brain by
reducing the number of activated microglia, and this reduction is correlated with an increase in
neurogenesis. Further work will be important to determine the mechanism of action of UCBMC in
the aged rats, including the possible role of the immune system in a T-cell mediated response, as
well as the affects of angiogenesis via the CD34+ stem cells. It will also be important in future
experiments to determine the duration that a single injection of UCBMC will elevated proliferation
in aged rats. Not only do the results of this study provide novel insight into the state of the aged
stem cell niche, the ability of the UCBMC to exert their effects while being administered minimally
invasively may make translation to the clinical setting more likely. For this reason it will be
important in future studies to determine the most efficacious dose and dosing regimen.
Nevertheless, this is the first time that a systemic injection of hematopoietic cells has been shown
to restore the regenerative potential of the aged brain, providing a novel insight into how the
regenerative potential of the aged stem cell niches could be restored.
Conclusions
The results demonstrate that a single intravenous injection of UCBMC in aged rats can
significantly improve the microenvironment of the aged hippocampus and rejuvenate the aged
neural stem/progenitor cells. Our results raise the possibility of a peripherally administered cell
therapy as an effective approach to improve the microenvironment of the aged brain.
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Figure 6: Proliferation is increased in aged rats following UCBMC treatment. To
determine if UCBMC could stimulate proliferation of the hippocampal neural progenitor/stem cells
rats received two i.p. injections of BrdU (50 mg/kg) and were sacrifice the following day. (A)
Quantification of the BrdU immunoreactive cell in the SGZ/GCL in aged rats 2 days after the
UCBMC treatment showed that there was a significant (p<0.005) increase in the number of BrdU
immunoreactive cells. (B,C) Photomicrographs of the dentate gyrus of a media-treated rat (B) and
a UCBMC-treated rat (C) shows the BrdU staining in those animals sacrificed 2 days after the
treatment. (D)The arrow in C points to a cluster of BrdU immunoreactive cells from the UCBMCtreated rat shown in D at higher magnification. (E) To determine how long proliferation might
remain elevated injections of BrdU (50 mg/kg) began 14 days after the treatment. Quantification
of the BrdU immunoreactive cells determine that the UCBMC-treated group had significantly
(p<0.01) more cells in the SGZ/GCL then the animals that received media alone. (F,G) BrdU
staining of the media-treated (F) and the UCBMC-treated (G) animals in the dentate gyrus of the
hippocampus 15 days after the treatment. (H) Arrow in G points to cells shown at higher
magnification in H. (scale bar for B,C,F,G is 100µm; scale bar for D,H is 25µm)
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Figure 7: 15 days after a UCBMC treatment neurogenesis is increase in aged rats.
To determine if UCBMC treatment could stimulate neurogenesis aged F344 rats were sacrificed
and immunohistochemical stained for DCX and BrdU. (A) A significant increase (p<0.05) in the
number of DCX+ cells, quantified in the SGZ/GCL, was found in the UCBMC treated rats. (B,C)
Photomicrographs show the dentate gyrus demonstrating the DCX immunohistochemistry in the
media-treated (B) and UCBMC-treated (C) rats. (D) A higher magnification photomicrograph of
area indicated in C shows a number of DCX+ cells showing the different morphologies of the
cells. (E) The results obtained with DCX were confirmed by BrdU. BrdU was injected i.p. for five
consecutive days after the single injection of UCBMC. 10 days after the last injection of BrdU the
animals were sacrificed. Compare to both a media control as well as an human adult peripheral
blood (PBMC) control the UCBMC treated animals had significantly more BrdU+ cells (p<0.01).
(F,G,H) Photomicorgaphs of dentate gyrus shows BrdU immunohistochemistry in the mediatreated (F), PBMC-treated (G) and UCBMC-treated (H) rats. (I,J) Immunofluorescence was
conducted to determine the phenotype of the BrdU+ cells. (I) An example of the cells double
labeled with BrdU+/NeuN+ (I; shown in orthogonal projection) and BrdU+/TUJ1+ (J; shown using
maximum projection). (scale bar for B,C,F,G,H is 100µm; scale bar for D is 25µm)
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Figure 8: The decrease in microglia activation correlates with neurogenesis. 15
days after the UCBMC treatment a significant reduction (p<0.05) was found in the number of OX6+ cells in the dentate gyrus of the aged rats (A). (B,C) Photomicrographs are shown of the
hippocampus of media-treated (C) and UCBMC-treated (C) rats. (D) A higher magnification
photomicrograph of area indicated by arrow in B. (E) A significant negative correlation (p<0.01)
was found between the number of OX-6+ cells and the amount of neurogenesis as determine by
the number of DCX+ cells. (F) The OX-6+ were further characterized based on morphology. The
cell on the left represents a typical ‘Type 1’ cell the cell on the right represents a typical ‘Type 2’
cell. Both ‘Type 1’ (p<0.05; G) and ‘Type 2’ (p<0.01; H) OX-6+ cells were significantly reduced in
the aged animals following UCBMC treatment, but there was a greater reduction in ‘Type 2’ cells
amounting to a four fold change. (scale bar for B,C is 200µm; scale bar for D is 25µm).
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Abstract
Cellular senescence occurs throughout the body during chronological aging of an
organism. A portion of senescence is independent of primary alterations to the stem cells, and is
dependent on the environment where the cells reside. While microglia have neuroprotective
capacities, their chronic activation can promote neurotoxic inflammation, thereby contributing
detrimental effects to the neural stem cell niche. The causes of age-related increases in microglial
activation and neuroinflammation are currently not well understood. Neuronally-expressed
fractalkine (FKN), acting via interaction with its receptor CX3CR1, can suppress excessive
microglia activation. To address the role of this chemokine system in hippocampal neurogenesis,
we examined the impact of interfering with FKN/CX3CR1 interactions in young and old rodents.
Disruption of FKN/CX3CR1 signaling in young adult rodents decreased survival and proliferation
of neural progenitor cells. These anti-neurogenic effects, resulting from loss of CX3CR1 function,
were reversed by IL-1β antagonism. Aged rats had decreased levels of hippocampal FKN protein
although interruption of CX3CR1 function in these animals did not affect neurogenesis. Moreover,
delivery of exogenous FKN reversed the age-related decrease in hippocampal neurogenesis in
aged rats but did not produce any effects in young animals. The results suggest that
FKN/CX3CR1 signaling has a regulatory role in modulating hippocampal neurogenesis via
mechanisms that involve indirect modification of the niche environment. As elevated
neuroinflammation is associated with many age-related neurodegenerative diseases, enhancing
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FKN/CX3CR1 interactions could provide an alternative therapeutic approach to slow
neurodegeneration, while also minimizing non-specific immunosuppressive responses.
Introduction
Adult neurogenesis is a lifelong process, continuing even in elderly humans (Eriksson et
al., 1998). However, studies in rodents have demonstrated a continual age-related decline in
neurogenesis (Rao et al., 2006; Ben Abdallah et al., 2008). An extensive list of neurogenic
regulators has been identified, many of which change as a result of aging (Drapeau and Nora
Abrous, 2008) making a unified theory to account for the age-related decrease in neurogenesis
unlikely. Yet, the potential importance of neurogenesis in some affective (Sahay and Hen, 2007)
and cognitive behaviors (Drapeau and Nora Abrous, 2008), as well as endogenous tissue repair
mechanisms, makes further investigation of neurogenic regulators warranted. Seminal studies
demonstrated that microglia can be detrimental to neurogenesis (Ekdahl et al., 2003; Monje et al.,
2003). Proinflammatory cytokines, including IL-1β, IL-6, and TNF-α, have been shown to act
directly on neural stem/progenitor cells (NPC)(Monje et al., 2003; Iosif et al., 2006; Koo and
Duman, 2008). Microglia are pleiotropic, and can also support neurogenesis through the
production of growth factors (Ziv and Schwartz, 2008). Therefore the involvement of microglia in
the neurogenic niche is not clear, as microglia can both increase and decrease neurogenesis.
Until recently, neurons were believed to be submissive to the effects of microglia; however, a
number of neuronal signals were found that can regulate microglia activation (Biber et al., 2007),
suggesting a neuron-microglia dialog.
One neuronally derived signal that has been shown to be important in regulating the neurotoxic
affects of microglia is the chemokine fractalkine (FKN; CX3CL1; neurotactin). In contrast to many
other chemokines, FKN binds and activates a single receptor, CX3CR1. Although there is some
debate concerning the cell types expressing these two molecules, in vivo FKN is principally
expressed on neurons while CX3CR1 is found on microglia (Harrison et al., 1998; Cardona et al.,
2006; Lauro et al., 2008). Previous reports establish that interactions between FKN and CX3CR1
contribute to maintaining microglia in a resting phase, partially controlling their neurotoxicity. FKN
acts in vitro as an anti-inflammatory molecule by down-regulating IL-1β, TNFα, and IL-6
production (Zujovic et al., 2000; Zujovic et al., 2001). FKN can also elicit neuroprotective effects
on pure neuronal cultures (Meucci et al., 1998; Meucci et al., 2000; Tong et al., 2000).
Moreover, mRNA and protein expression of CX3CR1 were found in isolated NPCs (Ji et al., 2004;
Krathwohl and Kaiser, 2004).
With age there is an increase in the number of activated microglia, which can suppress
neurogenesis (Gemma et al., 2007b; Bachstetter et al., 2008). We hypothesized that, as a
consequence of aging, FKN signaling becomes disregulated, which leads to increased microglial
activation and decreased neurogenesis. Our findings demonstrate for the first time that
FKN/CX3CR1 signaling is critical for the regulation of hippocampal neurogenesis.
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Materials and Methods
Animals. All experiments were conducted in accordance with the National Institute of
Health Guide and Use of Laboratory Animals, and were approved by the Institutional Animal Care
and Use committee of the University of South Florida, College of Medicine or the University of
Florida as appropriate. CX3CR1-deficient (CX3CR1GFP/GFP) mice, backcrossed to the C57BL/6
background for greater than 10 generations were obtained from JAX Laboratories (Bar Harbor,
Maine). Colonies of the CX3CR1+/GFP and CX3CR1GFP/GFP mice were maintained at the University
of Florida. Four-month-old male CX3CR1+/GFP and CX3CR1GFP/GFP littermates were used in the
experiments. Male Fisher 344 (F344) rats (NIA contract colony, Harlan Sprague Dawley,
Indianapolis, IN), were pair-housed in environmentally controlled conditions (12:12 h light:dark
cycle at 21 ± 1°C) and provided food and water ad libitum. Three age groups of rats used in this
study included: young (3 months old), middle aged (12 months old) and aged (22 months old).
Animals were excluded from the study if they became jaundiced, had pituitary tumors, or
developed post-surgery infections.
Surgical procedure. For all surgical procedures, rats were anaesthetized with
isofluorane. For intracerebroventricular infusion, a guide cannula was stereotaxically implanted in
the left ventricle (AP, −1.0; ML, 1.6; DV, −3.5 mm) and connected to an osmotic minipump, which
was inserted subcutaneously. For the first 7 days all rats received an osmotic minipump (Alzet
Model, 2001: pumping rate, 1.0 µL/h; total volume, 200 µL) filled with sterile saline, to allow time
for the rats to heal before drug treatment was started. After the first 7 days, a mid-scapular
incision was made and the saline pump was switched for the treatment pump for either an
additional 7 days (Alzet Model, 2001: pumping rate, 1.0 µL/h; total volume, 200 µL), 14 days
(Alzet Model, 2002: pumping rate, 0.5 µL/h; total volume, 200 µL), or 28 days (Alzet Model, 2004:
pumping rate, 0.25 µL/h; total volume, 200 µL). The treatments used in this study included: (1)
rabbit-anti rat CX3CR1 blocking antibody (α-CX3CR1) (10µg per day; Torrey Pines Biolabs, San
Diego, CA; Cat no. TP 501)(Milligan et al., 2004); (2) rabbit non-immune IgG (10µg per day;
Sigma-Adrich; Cat no. I-5006); (3) recombinant rat FKN (aa 22-100) chemokine domain (30ng per
day R & D systems, Inc.; Cat no. 568-FR/CF)(Milligan et al., 2004). (4) r-metHu IL-1Ra (10µg per
day; Amgen, Thousand Oaks CA). For controls, the proteins were heat-inactivated for 45 minutes
in a water bath at 90oC.
Thymidine analog labeling. Following the time line in Figure 2A animals received two
intraperitoneal (i.p.) injections of one or more thymidine analogs with a 12 hour interval.
Bromodeoxyuridine (BrdU) (5-bromo-2-deoxyuridine; Sigma, St. Louis, MO) was injected at dose
of 50 mg/kg. Equimolar solutions, to be equivalent to the 50 mg/kg of BrdU, were prepared from
chlorodeoxyuridine (CldU) (42.5 mg/kg; Sigma, St. Louis, MO) and iododeoxyuridine (IdU) (57.5
mg/kg; MP Biomedicals) as previously described(Vega and Peterson, 2005).
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Tissue collection and processing. For immunohistochemistry studies animals were
anaesthetized with pentobarbital (50 mg/kg, i.p.). The rats were transcardially perfused with
phosphate-buffered saline (PBS), followed by 4% paraformaldehyde in phosphate-buffered. The
brains were postfixed in 4% paraformaldehyde for 12 h, after which they were transferred into
30% sucrose in PBS for at least 16 h at 4°C. Exhaustive sagittal sections of the left hemisphere
were made at 40μm using a Microm cryostat (Richard-Allan Scientific, Kalamazoo Michigan) and
stored in cryoprotectant at 4°C. For biochemical experiments, animals were deeply anaesthetized
with isofluorane before decapitation. The brain was quickly removed and the brain regions were
dissected. Hippocampal tissues were dissected from both hemispheres and collected separately.
In animals that received treatment, only the hemisphere that received the treatment was used. In
naïve animals, both hemispheres were included. Homogenization of tissues was performed using
an ultrasonic cell disrupter, in a 1:10 weight/volume of ice cold cell lysis buffer (Cell Signaling
Technology, Inc.; Danvers, MA; Cat no. 9803) and phenylmethylsulphonyl fluoride, 1 mm (Sigma,
St. Louis, MO). Samples were centrifuged at 21,000 g at 4 °C for 15 min and supernatant was
collected. Determination of total protein, using a Bradford protein assay (BIO-RAD Laboratories,
Hercules, CA, USA) and an enzyme-linked immunosorbent assay (ELISA) were performed on the
same day to avoid repetitive thawing of samples. The ELISA for both rat IL-1β (eBioscience, Inc.;
San Diego, CA; cat no. 88-6010-22) and rat FKN (RayBiotech, Inc.; Norcross GA; Cat no. ELRFractalkine-001C) were performed using a commercially available kit following the manufacturer's
protocol.
Real-Time RT-PCR. Dissected tissues stored at -80oC were used for RNA isolation using
RNeasy mini-columns (Qiagen; Cat no. 74104) with on-column DNase treatment (Qiagen; Cat no.
79254) according to the manufacturer’s protocol. RNA quantity was determined and normalized
using Quant-iT™ RiboGreen® RNA Assay Kit (Invitrogen; Cat no. R11490). Integrity of the RNA
was confirmed on an agarose gel assessing the 18s and 28s rRNA bands. Reverse transcription
(RT) was done following the manufacturer’s protocol using High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems; Cat no. 4368814). A no template and a no RT control
were conducted to control for contamination. qPCR reaction was performed using SYBR® Green
PCR Master Mix (Applied Biosystems; Cat no. 4309155) following the manufacturer’s protocol,
with the exception of variable annealing temperatures (55oC-65oC) as determined most optimal
during primer validation. A melt curve beginning at 55oC and increasing by 0.5oC to 95oC every
10 sec with fluorescence measured at each interval. A single peak in the melt curve was used to
check for a single product. A standard curve that covers 3 logs was made of pooled cDNA from
all the rats and used each plate to check the efficiency of the reaction as determined by the slope
of the standard curve and to assess plate to plate variations. All samples were run in triplicate.
The primers that were used included; Rpl19 (NM_031103; sense: AATCGCCAATGCCAACTC;
antisense: CCCTTCCTCTTCCCTATGC) as the reference gene, to normalize the expression of
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FKN (NM_134455; sense: CGAGTTCTGCTGTCTACCAATCTG; antisense:
GAAGTGGTGGACGCTTGAGTAG). Relative gene expression was calculated by the 2-∆∆CT
method.
Immunohistochemistry and Immunofluorescence. Except where specifically
indicated, standard staining procedures were conducted on free-floating sections using every
sixth section for the entire hippocampus beginning with a random start and including sections
before and after the hippocampus to ensure that the entire structure was sampled. The standard
staining procedures used began with 0.3% H2O2 solution in 30% methanol to block endogenous
peroxidase activity (this step was omitted for immunofluorescence). Sections were blocked in
10% normal serum from the species that secondary antibody was raised in, with the addition of
0.1% Triton X-100. Sections were incubated, with primary antibody diluted in 3% normal serum
with 0.1% Triton X-100, overnight at 4°C. For immunohistochemistry biotinylated secondary
antibodies were diluted in 3% normal serum with 0.1% Triton X-100 and were incubated for 2
hours at room temperature. For immunofluorescence appropriate secondary antibody conjugated
to an Alexafluor probe (Molecular Probes, Eugene, OR) was applied for 2 hours. For
immunohistochemistry, enzyme detection was done using avidin-biotin substrate (ABC kit, Vector
Laboratories, Burlingame, CA) followed by color development in diaminobenzidine solution
(Sigma, St. Louis, MO). For BrdU, sections were pretreated with 50% formamide/2× SSC (0.3 M
NaCl, 0.03 M sodium citrate) at 65°C for 2 hours, rinsed in 2× SSC, incubated in 2N HCL for 30
minutes at 37°C, and washed with borate buffer (pH 8.5). For IdU and CldU, sections were
pretreated 2N HCL for 20 minutes at 37°C followed by a wash in borate buffer (pH 8.5). BrdU was
detected using a mouse anti-BrdU (1:100; Roche; Indianapolis IN; Cat no.11 170 376 001, clone
BMC 9318). CldU was detected with rat anti-BrdU (Accurate Chemicals, Westbury, NY Cat no
OBT003 clone: BU1/75 (ICR1)). For IdU, mouse anti-BrdU (Becton Dickinson Bioscience, San
Jose, CA; Cat no.347580, clone B44), was used at a dilution of 1:500. Doublecortin (DCX) is a
marker of migrating neurons that is expressed for approximately three weeks after the cell is born
and has been shown to be a reliable indicator of neurogenesis(Rao and Shetty, 2004; CouillardDespres et al., 2005). For DCX immuno-detection, incubation in primary antibody was done for 36
hours at 4°C using a polyclonal goat antibody C-terminus of human DCX (1:200; SC-8066, Santa
Cruz biotechnology, Santa Cruz, CA, USA). Ki67 is expressed in cells G1 through M phase of the
cell cycle (Scholzen and Gerdes, 2000). For detection of Ki67, a rabbit anti-human Ki67 antibody
(NCL-Ki67p; Novocastra Laboratories/Vision BioSystems, Newcastle upon Tyne, UK) was used
at a dilution of 1:500. Mature neurons were stained with the marker NeuN (1:100; Chemicon,
Temecula, CA). For OX-6 immuno detection a monoclonal antibody directed against the rat major
histocompatibility II (MHCII) (RT1B, Becton, Dickinson Pharmingen, San Diego, CA, USA) was
used at a concentration of 1:750. For microglia analysis in mice, two antibodies were used;
mouse major histocompatibility II(I-A/I-E, Becton, Dickinson Pharmingen, San Diego, CA, USA;
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Cat no. 556999 Clone: M5/114.15.2); and rat anti-mouse CD45 (AbD Serotec; Raleigh, NC;
1:10,000; Clone: YW62.3; Cat no. MCA1031G). Detection of FKN was acomplished using a goat
anti-rat polyclonal antibody that recognizes the chemokine domain of FKN at a concentration of
1:100 (R&D Systems; Minneapolis, MN; Cat no. AF537).
Quantification and imaging: To determine cell numbers, the optical fractionator method
of unbiased stereological cell counting techniques (West et al., 1991) was used with a Nikon
Eclipse 600 microscope and quantified using Stereo Investigator software (MicroBrightField,
Colchester, VT). Due to the low number of BrdU+, CldU+, Idu+, and DCX+ cells in the aged
animals, the virtual grid and counting frame were both 125μm x 125μm in order to count all the
cells that were present in the section. For all other counts, sampling was optimized to count at
least 200 cells per animal with error coefficients less than 0.07. Outlines of the anatomical
structures were done using a 10x/0.45 objective and cell quantification was conducted using a
60x/1.40 objective. An Olympus FluoView FV1000 confocal microscope was used for all
Immunofluorescence photomicrographs, only linear adjustments (brightness and contrast) were
made to the figures. When quantification of percentage of positive cells was determined, Z stacks
were created at 1μm intervals throughout the 40μm of the sections with a guard region of 2μm
excluded from top and bottom of the Z stack. The Z stacks were rotated in all planes to verify
double labeling.
Statistical analyses: Data are presented as mean±SEM. Statistical analysis was
performed using an unpaired, two-side t-test, or a one-way ANOVA followed by unpaired t-test.
Correlations were tested using a Pearson product-moment correlation coefficient. A value of
p<0.05 was considered to be significant.
Results
CX3CR1-deficient mice have decreased hippocampal NPC proliferation and
neurogenesis. Previous studies suggest that CX3CR1 suppresses the neurotoxic effects of
activated microglia (Cardona et al., 2006). However, in the absence of a neurotoxic insult,
CX3CR1GFP/GFP mice lack any obvious phenotype, and appear to have normal brain development
(Jung et al., 2000; Cook et al., 2001; Haskell et al., 2001). To date, no studies have investigated
whether loss of CX3CR1 signaling results in changes in adult neurogenesis. To begin to address
this issue, the number of DCX+ cells in the subgranular zone (SGZ) and granular cell layer (GCL)
of the dentate gyrus in CX3CR1-expressing and deficient mice were quantified using the optical
fractionator method of design based stereology. A significant decrease (t(9)=3.857; p=0.0062) in
the number of DCX+ cells in the CX3CR1GFP/GFP mice was found as compared to the CX3CR1+/GFP
mice (Fig. 10A). To determine if this decrease might be due to reduced proliferation, mice were
injected twice (8 hours interval) with BrdU (50mg/kg) and the mice were euthanized on the
following day. Quantification of the number of BrdU+ cells revealed a significant decrease
(t(13)=2.513; p=0.026) in the number of BrdU+ cells in the CX3CR1GFP/GFP mice compared to the
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CX3CR1+/GFP mice (Fig. 10B). Figure 1C shows that CX3CR1+ cells (green) were widely distributed
in the dentate gyrus, with a typical appearance of ramified microglia. The CX3CR1+ cells in the
SGZ had a morphological appearance of microglia and were located in close proximity to the
NPC. To determine whether neurons or astrocytes also expressed CX3CR1, sections from
CX3CR1+/GFP mice and CX3CR1GFP/GFP mice were stained for GFAP (blue), BrdU (red), and NeuN
(Magenta) (Fig. 10D) and for DCX (red) (Fig.10E-F). Colocalization of GFP with GFAP, NeuN, or
DCX was not observed. Colocalization of BrdU and GFP was rarely seen, and most likely
represented proliferating microglia and not expression of CX3CR1 on a NPC. Figure 10F-G
shows CX3CR1+ cells adjacent to the DCX+ cells, with the CX3CR1+ cell processes interdigitating
with the DCX+ cells (Fig. 10F) suggesting an important cell-to-cell regulation of the NPCs and the
maturation and survival of the adult born neurons.
Proliferation of NPCs is decreased by α-CX3CR1 treatment in young but not middle
aged or old rats. To develop a pharmacological model of decreased FKN signaling, a blocking
antibody to CX3CR1 was employed. This model allowed for transient loss of signaling as
compared to the mouse model that, as a result of the permanent developmental loss of FKN
signaling, might evoke compensatory mechanisms. To determine if blocking of CX3CR1 would
cause a decreased NPC proliferation and neurogenesis as seen in the mouse model, we infused
blocking antibody to CX3CR1 for 7 days via an osmotic minipump to the left lateral ventricle.
Young adult rats (3 months old), middle aged rats (12 months old) and old aged rats (22 months
old) were injected with BrdU on the 6th day of treatment. The animals were euthanized on the
following day and sections of the hippocampus were evaluated for proliferation and short-term
survival of the NPCs. Quantification of the number of BrdU+ cells in the SGZ showed a significant
decrease (t(10)=4.688; p=0.0009) in the number of BrdU+ cells in the α-CX3CR1-treated rats
compared to the non-immune IgG-treated animals (Fig.11A). To confirm the BrdU results, the
number of Ki-67+ cells were quantified in the SGZ. A significant decrease (t(5)=3.596; p=0.0156)
was found in the number of Ki-67+ cells in the α-CX3CR1-treated rats compared to the nonimmune IgG-treated animals (Fig.11B). This was also confirmed by quantification of the number
of DCX+ cells. In the young adult rats a significant decrease in the number of DCX+ cells was
found following treatment for 7 days with α-CX3CR1 (t(5)=2.629; p=0.0466)( Fig.11C). However no
significant differences in the number of BrdU+ cells (Fig.11A), Ki-67+ cells (Fig.11B), or in the
number of DCX+ cells (.Fig.11C), were found in the middle aged rats or old aged rats following
treatment with the blocking antibody.
FKN reversed the age-related decrease in neurogenesis, but had no effect in young
or middle aged rats. To further investigate whether FKN/CX3CR1 signaling could modulate
hippocampal neurogenesis, we treated the three different age groups of rats with 30ng/d of
recombinant rat FKN. Following the same protocol used for the α-CX3CR1 study, FKN was
continuously infused into the left ventricle by an osmotic minipump for 7 days. In the first
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experiment, BrdU was injected 6 days following the beginning of the FKN treatment and the
animals were euthanized on day 7 (Fig.12A). A significant increase (t(10)=2.639; p=0.0248;
Fig.12B) in the number of BrdU+ cells in the aged rats treated with FKN was found as compared
to the aged rats treated with heat-inactivated (HI)-FKN (Fig.12A). Quantification of the number of
DCX+ cells in the aged rats after 7 days of FKN treatment indicated no significant difference
between the two groups (Fig 12C). In the young adult and middle aged rats, FKN treatment did
not produce any measurable changes in the number BrdU+ cells (Fig.13A), or in the number of
DCX+ cells (Fig.13B).
FKN treatment in aged rats mainly affects proliferation. To determine whether the
disruption in FKN/CX3CR1 signaling induced changes in proliferation or survival of the newly born
cells, we used a multiple thymidine analog approach. Both CldU and IdU were used to date new
born cells at 2 different time points (see timeline Fig.12A). FKN was delivered via an osmotic
minipump to the left lateral ventricle for 15 days. One day prior to the beginning of the treatment
aged rats were injected with CldU (b.i.d.; 42.5 mg/kg; equimolar to BrdU). IdU was injected on
day 6 (b.i.d.; 57.5 mg/kg; equimolar to BrdU), allowing an additional 7 days of treatment to
measure the effect of treatment on the survival of IdU+ cells. Stereological quantification using an
optical fractionator demonstrated no effect of FKN treatment in the number of CldU+ cells (Fig
12D). In contrast, there was a significant increase (t(7)=3.831; p=0.0065; Fig.12E) in the number
of IdU+ cells in the FKN-treated rats compared to the HI-FKN-treated rats. By comparing the
number of BrdU+ cells in the first experiment to the number of IdU+ cells in the second experiment
it is possible to determine if there were combined effects on survival and proliferation following
treatment, or if these effects were limited to proliferation. In the aged rats, FKN increased the
number of IdU+ cells. Comparison of the number of IdU+ cells to the number of BrdU+ cells,
demonstrated that FKN treatment increased the survival by about 18%, but these changes were
within 95% confidence interval (FKN 82.7%±16.45%; HI-FKN 64.7%±21.0%; mean±SD). The
number of DCX+ cells was quantified to determine if the increased number of BrdU+ and IdU+
cells translated to an increase in DCX+ cells. After 14 days of treatment there was a significant
increase (t(8)=2.945; p=0.0116; Fig.12H) in the number of DCX+ cells in the FKN group compared
to the HI-FKN group. The increase in the number of IdU+ cells was found to significantly correlate
with the number of DCX+ cells (Pearson r=0.933; p=0.0002; Fig 12I).
Expression of FKN in the rat hippocampus. As we were able to reverse the agerelated decline in neurogenesis through the addition of recombinant FKN in the aged rats, we
hypothesized that FKN might be altered with age. FKN levels in hippocampal tissue homogenates
from young and aged rats were analyzed by ELISA. A significant decrease (t(16)=4.374; p=0.0005;
Fig. 12A) in the level of FKN protein in the aged rats, compared to the young rats, was evident.
However, mRNA levels of FKN were unaltered in the aged rats compared to the young rats
(Fig.13B). We further investigated the protein localization of FKN in the dentate gyrus. Figure 13C
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shows a photomicrograph of staining with DAPI (blue), FKN (green), and Tuj1 (red). While FKN
was abundantly expressed on the cell bodies of presumable neurons in the GCL, FKN staining
was not found on Tuj1+ cells. Moreover, photomicrographs of Ki-67 (red) and FKN (green)
(Fig.13D,E) also demonstrated a lack of FKN expression on the proliferating cells. These data
indicated that FKN is not expressed on immature neuronal cells; however, it is not clear exactly
when FKN begins to be expressed on neurons.
CX3CR1 blocking antibody increased IL-1β. To determine whether inhibition of
CX3CR1 activity would lead to an increase in IL-1β protein levels, the CX3CR1 blocking antibody
was infused in young rats for 28 days via an osmotic minipump. The 28 day time point was
chosen to ensure that if there was a difference in IL-1β levels, the difference would be large
enough to be easily detected by a standard ELISA. In Figure 15, we found that there was a
significant effect in the amount of IL-1β following treatment for 28 days with the CX3CR1 blocking
antibody (F(2,16)=16.89; p=0.0002). Compared to either the saline treated rats (t(11)=5.179;
p=0.0003) or the non-immune IgG treated rats (t(7)=2.630; p=0.0339) the α-CX3CR1 treated rats
had a significant elevation in IL-1β. The saline treated rats and the non-immune IgG treated rats
were also significantly different from each other (t(10)=4.064; p=0.0023). Nevertheless, the data
indicates that the pharmacological antagonism of CX3CR1 leads to increased production of IL-1β.
IL-1β mediates the effects of α-CX3CR1 treatment. To determine if the anti-proliferative
effects of the CX3CR1 blocking antibody were dependent on IL-1β, young rats were infused with
IL-1 receptor antagonist (IL-1Ra) along with either the α-CX3CR1 or non-immune IgG, following
the same 7 day protocol as described earlier. A One-Way ANOVA revealed a significant effect
(F(3,17)=5.476; p=0.0081) in the number of BrdU+ cells (Fig.16A). To determine if the addition of IL1Ra could have an effect on NPC proliferation a comparison was made between the non-immune
IgG groups that received an active IL-1Ra or a heat-inactivated (HI)-IL1Ra. No difference was
found as a result of IL-1Ra, suggesting that antagonizing the effects of IL-1β in the control rats
that received the non-immune IgG did not alter proliferation (IgG+IL-1Ra n=6; IgG+HI-IL1Ra
n=4). The next comparison was made between the rats that received a heat-inactivated IL-1Ra
along with the either the α-CX3CR1 or IgG. A significant decrease (t(7)=3.499; p=0.010) was found
in the number of BrdU+ cells in the rats that received the α-CX3CR1 compared to the IgG group
(α-CX3CR1+HI-IL-1Ra 4236±422.6 n=5). The results of this comparison replicate the findings in
Fig.11B, demonstrating that without, an active IL-1Ra, treatment with α-CX3CR1 decreases
proliferation of NPCs. A significant decrease was also found between the α-CX3CR1+HI-IL1Ra
treated group and the non-immune IgG treated group that received the active IL-1Ra (t(9)=3.373;
p=0.0082). Finally, to determine if the effects of the blocking antibody were mediated through IL1β we compared the rats that received the blocking antibody along with the active or inactive IL1Ra. In the α-CX3CR1 treated rats the addition of IL-1Ra was able to prevent the decrease in
proliferation that occurred following treatment with the α-CX3CR1. There was a significant
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difference in the number of BrdU+ cells (t(9)=4.220; p=0.0022); such that, the rats which received
the blocking antibody with the inactive IL-1Ra had fewer cells than the rats that received the
blocking antibody and an active IL-1Ra (α-CX3CR1+IL1Ra n=6; α-CX3CR1 HI-IL-1Ra n=5). The
effects on proliferation following treatment with α-CX3CR1 appear to be mediated through IL-1β
as the IL-1Ra was able to completely attenuate the decrease in proliferation following treatment
with α-CX3CR1.
To determine if IL-1β also mediated the decrease in neurogenesis found after treatment
with α-CX3CR1, the number of DCX+ cells was quantified in the rats that received IL-1Ra along
with α-CX3CR1 or non-immune IgG. After seven days of treatment a significant effect was found
(F(3,15)=7.615; p=0.0025)(Fig.16B). To confirm the results from the two earlier experiments in the,
CX3CR1GFP/GFP mice, and the initial experiment in rats, that demonstrated that loss of CX3CR1
function caused a decrease in the number of DCX+ cells, a comparison was made between the
rats that received the inactive IL-1Ra along with the α-CX3CR1 or non-immune IgG. A significant
(t(7)=2.441; p=0.0447) reduction in the number of DCX+ cells was found in the rats that received
the heat-inactivated IL-1Ra+ α-CX3CR1 group compared to the matching non-immune IgG group
(HI-IL-1Ra+ α-CX3CR1 n=5; HI-IL-1Ra+IgG n=4). Rats that received the active IL-1Ra along with
α-CX3CR1 showed the significant (t(8)=2.441; p=0.0358) decrease in the number of DCX+ cells
induced by α-CX3CR1 was prevented by the addition of IL-1Ra (IL-1Ra+ α-CX3CR1 n=5). Rats
that received the IL-1Ra with α-CX3CR1 were not significantly different than the IgG+HI-IL-1Ra
group with respect to the number of DCX+ cells. The results demonstrate that the decrease in
DCX+ cells following blocking antibody treatment was mediated through IL-1β.
An unexpected finding was the physiological role of IL-1β in regulating neurogenesis. When the
IL-Ra was given to the non-immune IgG group (IL-1Ra+IgG n=5) a significant reduction in the
number of DCX+ cells was found compared to the non-immune IgG group that received the heatinactivated IL-1Ra (t(7)=6.573; p=0.0003). As there was not a significant decrease in proliferation
in the IL-1Ra+IgG group the DCX data suggests that a physiological level of IL-1β is important for
the survival of the DCX+ cells, a similar finding was previously reported (Spulber et al., 2008). The
number of BrdU+ cells (green) that were also DCX+ (red) were quantified (Fig.16C), and no
differences in the number of BrdU+/DCX+ cells was found between any of the groups in the
percentage of double-labeled cells (81.75%±6.3%).
CX3CR1 blocking antibody decreased survival of cells born prior to treatment. After
seven days of α-CX3CR1 treatment, the number of DCX+ cells was significantly decreased in the
young adult rats (Fig.16B). The decrease in DCX+ cells could be due to decreased proliferation,
as measured at day six (Fig.16A). Alternatively, treatment with α-CX3CR1 could also decrease
the survival of the immature neurons leading to a decrease in DCX+ cells. To determine if αCX3CR1 treatment affected survival of cells born prior to treatment, CldU was injected one day
before the beginning of the 14 days of infusion of non-immune IgG or α-CX3CR1. Figure 2A
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shows the different time points that were compared. Quantification of the number of CldU+ cells
demonstrated a significant decrease (t(7)=3.566; p=0.0091; Fig. 16D) in the number of CldU+ cells.
After 14 days of treatment, in the rats that received α-CX3CR1 fewer of the cells that were born
the day before treatment began survived compared to the non-immune IgG group. Figure 17
shows CldU+/NeuN+ cells in the non-immune IgG group (Fig.17A) and α-CX3CR1 group
(Fig.17B).
The preceding experiments demonstrated that α-CX3CR1 treatment decreased
proliferation of NPCs. To determine if α-CX3CR1 treatment could alter the survival of cells born
during the treatment, IdU was injected on day six of a 14 day of treatment. Day six was chosen
so that a comparison could be made between the number of IdU+ cells and BrdU+ cells
quantification from the earlier experiment (Fig.16A). In the α-CX3CR1 treatment group
significantly (t(7)=2.506; p=0.0406; Fig. 16E) fewer IdU+ cells were found compared to the nonimmune IgG. To determine if there was an effect on survival or if the effects were limited to
proliferation, the number of BrdU+ cells were compared to the number of IdU+ cells. Comparisons
of BrdU+ to IdU+ revealed no difference between the treatment groups (α-CX3CR1
49.6%±10.11%; IgG 50.7%±7.9%; mean ± SD), demonstrating that the decrease in the number of
IdU+ cells was due to a decrease in proliferation and not survival. A decrease in survival was
seen in the cells born prior to treatment. These results suggest, that following treatment with αCX3CR1, the niche environment becomes unfavorable for the survival of the new born cells, and
the cells born before the change in environment die. After the change in environment, there is a
decrease in proliferation but not survival as the number of cells born is limited to what the
environment can support. The changes in the niche environment translated to a decrease in
neurogenesis in the α-CX3CR1 group. In rats that were treated for 14 days, a significant decrease
(t(7)=2.690; p=0.0311; Fig. 16F) was found in the number of DCX+ cells in the α-CX3CR1 group
compared to the non-immune IgG treated group.
FKN is necessary to maintain microglia in an unactivated state. FKN/CX3CR1 has
been proposed to maintain microglia in a quiescent resting state. The expression of MHC Class II
on microglia is induced when the cell becomes activated. To determine if microglia became
activated following the CX3CR1 blocking antibody treatment, the number of cells expressing MHC
Class II was quantified using the marker OX-6. In the young adult rats the entire hippocampus
was used as the region of interest in order to sample a large enough population of cells, due to
the few OX-6+ cells in young adult control rats. Following 7 days (F(3,18)=3.644; p=0.0326;
Fig.18A) or 15 days (t(8)=2.653; p=0.0291; Fig.18B) of treatment there was a significant effect in
the number of OX-6+ cells. At 7 days, the group of rats that were treated with the α-CX3CR1 and
the heat-inactivated IL-1Ra (HI-IL-1Ra+ α-CX3CR1; n=5) had significantly more OX-6+ cells
compared to the non-immune IgG treated rats with either the inactive IL-1Ra (HI-IL-1Ra+IgG;
n=5) (t(8)=2.591; p=0.0321) or active IL-1Ra (IL-1Ra+IgG; n=5) (t(8)=2.412; p=0.0423). The group
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that received the α-CX3CR1 blocking antibody along with the active IL-1Ra was not significantly
different from any of the other groups (IL-1Ra+ α-CX3CR1; n=6). At 15 days a similar significant
increase in the number OX-6+ cells was found in the α-CX3CR1 treated group compared to the
non-immune IgG treated group
Aging is associated with increased activation of microglia. We hypothesized that a portion
of the microglia activation might be a result of a decreased inhibitory signaling by FKN. To test
this hypothesis, we quantified the number of OX-6+ cells in SGZ/GCL only. In the aged rats there
was a large enough population of OX-6+ cells in this region of interest to sample adequate
number of cells following treatment with FKN or HI-FKN. After 14 days (Exp.2) of FKN treatment,
a significant decrease in the number of activated OX-6+ cells was found (t(8)=3.030; p=0.0163;
Fig.18C) in the FKN group compared to the HI-FKN group. Previous studies have shown a
negative correlation between the number of activated microglia and the amount of new cells that
are born (Ekdahl et al., 2003; Bachstetter et al., 2008); a correlation analysis was conducted to
determine if similar effect was observed following FKN treatment. In the aged rats, after 14 days
of treatment with FKN, the number of OX-6+ cells was found to significantly negatively correlate
(r(9)=-0.7425; p=0.0219; Fig.18D) with the number of IdU+ cells (Exp.2; Fig.12E). We did not find a
significant correlation between the number of CldU+ cells or DCX+ cells and the number of OX-6+
cells (data not shown). Furthermore, in aged rats treated for 7 days with FKN we did not find any
differences in the number of OX-6+ cells (data not shown).
Discussion
Two questions were addressed by the present study: Is CX3CR1/FKN signaling important
for maintaining adult hippocampal neurogenesis? Could a disruption in CX3CR1/FKN signaling
contribute to the age-related decline in neurogenesis? We demonstrated three main findings: first,
loss of function of CX3CR1 in young adult rodents, mice and rats, resulted in a significant
decrease in hippocampal neurogenesis; second, administration of exogenous FKN reversed the
decline in neurogenesis associated with aging; third, IL-1Ra protected against the decrease in
hippocampal neurogenesis induced by blocking CX3CR1 function.
Our results suggest that neurons which are the major producers of FKN, and microglia which
express CX3CR1 are actively involved in a cross-talk to regulate the production of new neurons.
During development the expression of FKN in the brain has been shown to increase nearly 10
fold in four week old mice compared to one day old mice (Labrada et al., 2002). In our study, we
found that FKN expression was absent on immature neurons, suggesting that FKN might be
important in protecting mature neurons from the consequences of overactive microglia. It is also
possible that mature neurons, through an indirect mechanism, could communicate with microglia
to regulate the addition of new neurons into the mature circuit. This could occur via IL-1β
decreasing the proliferation of the NPCs. Furthermore, FKN might also be involved in the removal
of apoptotic cells, as FKN has been shown to enhance phagocytosis of apoptotic cells (Fuller and
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Van Eldik, 2008). Removal of apoptotic cells is an important mechanism to make room for new
cells to be added, and to prevent secondary necrosis of the apoptotic cell which occurs if dead
cells are not quickly removed.
FKN is anchored to the cell membrane, but can be cleaved off the membrane by
metalloproteinase 10 (ADAM10) (Hundhausen et al., 2003) or by TNF-a converting enzyme
(TACE / ADAM17)(Garton et al., 2001). FKN signaling, when decreased beyond a physiological
level, as in the case of young rats treated with α-CX3CR1, was observed to decrease
neurogenesis. On the other hand, when FKN signaling was already decreased, as we observed
in the aged control rats, a further loss did not affect neurogenesis. Similarly in the young control
rats, in which FKN levels are normal, addition of exogenous FKN did not alter neurogenesis.
However, our current study doesn’t address if the membrane or shed form of FKN might have
unique roles in regulating neurogenesis. Therefore, future studies are warranted to discern if
there are different mechanisms of actions produced by the different forms of FKN.
CX3CR1/FKN signaling is proposed to keep microglia in a non-proinflammatory state (Cardona et
al., 2006), as inhibition of FKN/CX3CR1 function has been shown to increase microglial activation
and increase production of TNFα and IL-1β (Zujovic et al., 2000; Mizuno et al., 2003; Cardona et
al., 2006). We found that inhibition of FKN/CX3CR1 function increased microglia activation. This
finding is in agreement with our hypothesis that disruption of CX3CR1 function leads to an
increase in microglia activation, which could be ultimately responsible in negatively regulating
neurogenesis. However, we did not find increased microglia activation as measured by MHC-II
expression, in the CX3CR1GFP/GFP mice compared to the heterozygote littermates (data not
shown). A possible explanation could be that permanent loss of CX3CR1 since birth results in
compensatory changes in the expression of cell surface markers of microglia activation. An
additional discrepancy was found in the aged rats treated with FKN for 7 days, where we saw an
increase in proliferation but no changes in the number of MHC-II+ cells, or DCX+ cells. Thus, it is
possible that FKN does not exert its effect directly through microglia. Alternatively, alterations in
MHC-II expression may not be the best indicator of the activation state of microglia induced by
alteration in FKN/CX3CR1 axis. This may be because MHC-II expression can occur in activated
microglia which can be classically activated to produce pro-inflammatory cytokines, as well as in
microglia that are alternatively activated to produce growth factor and anti-inflammatory
cytokines. However after 14 days of FKN treatment there was a significant reduction in the
number of MHC class II+ cells. Furthermore, we found a negative correlation between the number
of MHC-II+ cells with the number of IdU+ cells. While we cannot rule out the possibility that other
pathways are involved in the effects observed in our study, our data in aged rats strongly indicate
that FKN/CX3CR1 suppression of microglia activation, at least in part, modulates hippocampal
neurogenesis in aged rats.
Aging is associated with chronically elevated levels of IL-1β in the hippocampus (Gemma
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and Bickford, 2007). IL-1β has been shown to act directly at the NPC via the IL-1R1 to block cell
cycle progression and thereby decrease proliferation (Koo and Duman, 2008). Moreover, we
have recently shown that reducing the levels of IL-1β in aged rats is able to reverse some of the
age-related decreases in neurogenesis (Gemma et al., 2007b). CX3CR1 regulates the PI3K
pathway in microglia resulting in inhibiting the production of IL-1β (Re and Przedborski, 2006).
We found disruption of FKN signaling by a blocking antibody to the FKN receptor CX3CR1
caused an increased production of IL-1β. In the young adult rats we found that IL-1Ra
completely reversed the decrease in proliferation and neurogenesis that resulted after blocking
CX3CR1, suggesting that the effects of FKN on NPC proliferation are mediated through inhibition
of IL-1β.
Several studies have shown that FKN can have direct effects on neurons in vitro (Meucci et al.,
1998; Meucci et al., 2000; Tong et al., 2000). Using the GFP expression in the CX3CR1+/GFP mice
we found that the receptor for CX3CR1 was not found on neurons in the GCL, which confirmed
earlier findings in vivo that found CX3CR1 expression only in microglia (Harrison et al., 1998;
Jung et al., 2000; Cardona et al., 2006). Moreover, it has been recently shown that the survival
effects of FKN on primary neuron al culture was dependent on microglia (Lauro et al., 2008).
These results suggest that FKN acts via the microglia expressed CX3CR1 to regulate IL-1β which
then acts on the NPCs and neurons.
The second major finding of this study is an age-related disruption of FKN/CX3CR1
signaling. Cardona et al. (06) demonstrated in a number of models of neurodegeneration that loss
of neuron-microglia interactions by disruption of FKN/CX3CR1 signaling results in increased
microglia neurotoxicity and an associated worsening in disease pathology. It is unclear if the
disregulation of FKN signaling observed in our study is a cause or consequence of the increased
activation of microglia and neuroinflammation that occurs as a result of normal aging. Levels of
FKN in aged control rats were decreased in the hippocampus compared to young adult rats. The
lack of alteration in FKN mRNA suggests that post-translational changes are responsible for the
age-related decrease in FKN. Therefore, as a result of normal aging, the alterations in
FKN/CX3CR1 signaling are mostly likely a result of changes in ligand levels or post-translational
processing and not alterations to the receptor as administration of exogenous FKN restored the
age-related loss in neurogenesis. Age-related changes in the FKN/CX3CR1 axis have been
characterized in other scenarios. There are at least two common single nucleotide
polymorphisms in the promoter region of CX3CR1 which cause reduced CX3CR1 function,
including decreased adhesion, signaling, and chemotaxis of CX3CR1+ cells. These
polymorphisms have been associated with reduced risk for atherosclerosis (McDermott et al.,
2003) and increased risk of age-related macular degeneration (Tuo et al., 2004; Combadiere et
al., 2007). Moreover, our results are in agreement with data obtained in Alzheimer’s disease
patients in which lower levels of soluble plasma FKN were correlated with lower mini-mental
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status examination score(Kim et al., 2008). Additionally, APP transgenic mice showed a
decrease in neuronal levels of FKN at 9 months of age (Duan et al., 2008).
Conclusion
Microglia have been demonstrated to be both pro and anti-neurogenic depending upon
their activation state. This study demonstrates that neurons may actively regulate microglia in the
neurogenic niche, and are not necessarily passive actors to the effects of microglia. However with
age, the dialog between neuron and microglia via FKN appears to be disrupted, but can be can
be re-established through the addition of recombinant FKN. Inflammation is believed to be a
contributing factor to the pathogenesis of a number of neurodegenerative diseases, many of
which are age-related, including: Alzheimer’s disease, Parkinson’s disease, and age-related
macular degeneration. Understanding the mechanism by which age-related alterations in the
inflammatory response contribute to the progression of the aforementioned neurodegenerative
diseases is key to developing therapeutic interventions for the age-related neurodegenerative
condition.
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Figure 9: CX3CR1GFP/GFP mice have diminished hippocampal neurogenesis. (A)
Unbiased stereology revealed a significant decrease (p=0.0062) in the number of DCX+ cells in
the hippocampus of adult male CX3CR1GFP/GFP mice (n=5) compared to heterozygote control
(n=4). (B) Quantification of the number of cells that were proliferating during the proceeding 24
hours, as determined by the incorporation of BrdU, was significantly fewer (p=0.026) in the
CX3CR1GFP/GFP mice (n=9) compared to control (n=6). (C) CX3CR1 (GFP) and dapi (blue),
demonstrate the localization of the CX3CR1 cells in the dentate gyrus. (D) Localization of
CX3CR1 (GFP) cells was not found in NeuN+ cells (magenta) or in GFAP+ cells (blue), and only
rarely in BrdU+ cells (red). (E). Low power photomicrograph of DCX+ cells (red) and CX3CR1
(GFP) cells are also shown in higher power in maximum projection of confocal z-stack (F) Arrow
indicated CX3CR1 (GFP) cells that are in close proximity to the DCX cells.
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Figure 10: Proliferation is
decreased by α-CX3CR1. Three ages of
male F344 rats were treated with αCX3CR1 or the IgG control for 7 days via
an osmotic minipump to the left lateral
ventricle. On day 6 of treatment BrdU
was injected twice 8 hours apart. The
animals were sacrificed on day 7. (A)
Quantification of the number of BrdU+
cells in the subgranular zone, in the
young adult rats revealed a significant
decrease (***p=0.0009) in the number of
adult young rats following α-CX3CR1
(n=6) compare to IgG control (n=6). In the
middle aged rats and the aged rats there
was no significant differences in the
number of BrdU+ cells in the IgG control
group compare to the α-CX3CR1 treated
group. (B) The decrease in BrdU+ cells in
the young rats treated with α-CX3CR1
(n=4) compare to IgG control (n=3) was
confirmed by Ki-67, as a significant
decrease was also found in the number
of Ki-67+ cells (*p=0.0156). Confirming
the BrdU data, in the aged rats no
difference in the number of Ki-67+ cells
was found. (C) The number of DCX+
cells was also found to be significantly
decreased (*p=0.0466) in the young adult
rats following α-CX3CR1 treatment (αCX3CR1 n=3; IgG n=4), but no effect was
found in the middle aged rats or old aged.
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Figure 11: FKN reverses the agerelated decrease in neurogenesis.
(A) Timeline: In experiment 1
treatment lasted for 7 days, with
injections of BrdU occurring at day 6.
In experiment 2, treatment lasted for
14 days, with injections of CldU
occurring at day -1 and injections of
IdU occurring at day 6. BrdU was
used to study the affects of the
treatment on proliferation of
hippocampal NPC. CldU was used to
study the affects of treatment on the
cells born prior to the treatment. IdU
was used to study the affects of
survival of the cells born after
treatment and to make direct
comparisons with BrdU data. (B) A
significant increase (p=0.0248) in
proliferation (FKN n=6; HI-FKN n=6)
but not in the number of DCX+ cells
(FKN n=4; HI-FKN n=6) (C) was
found in the aged treated with FKN
for 7 days. (D) In the second
experiment, in the cells born before
treatment began (labeled with CldU)
and lived for 15 days no difference
was found between groups (FKN
n=5; HI-FKN n=4). When the cells
were labeled at the same time point
as BrdU (B) with IdU a significant
increase (p=0.0065; E) in number of
+

IDU cells was found in the FKN treated group (FKN n=5; HI-FKN n=4), (H) which appeared to
translated to the significant increase (p=0.0116) in the DCX+ as the two makers were strongly
correlated (r=0.933; p=0.0002) (I).
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Figure 12: FKN exerts proliferative effects in aged rats. Rats were injected with BrdU
on day 6 of a 7 day treated of FKN (30ng/d) or a heat-inactivated (HI)-FKN control. (A). No
differences were found in the number of BrdU+ cells in the young or middle aged animals
between treatment groups. As shown in figure 2B, in the aged rats a significant increase in the
number of Brdu+ cells was found (p=0.0248) in the FKN treated rats compare to the control rats.
(B) Quantification of DCX+ cells demonstrated an absence of a treatment effect in all three ages
after 7 days of treatment. BrdU and DCX data from the 22 mo old rats was also presented in Fig
2B and 2C respectively, and was re-presented in the supplementary data for comparison
purposes.
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Figure 13: Expression of FKN in the hippocampus. Quantification of protein (A) and
mRNA (B) levels of FKN in the hippocampus of young adult and aged rat, demonstrated a
significant decrease in protein levels of FKN (p=0.0005) (n=9 per group), but not in mRNA levels
(n=6 per group). (C) FKN expression (green) was not found on Tuj1+ (red) cells, but was
expressed on the majority of the cells (dapi: blue) in the GCL. (D) and (E), shows low and high
magnification respectively, of Ki-67 staining (red) and FKN staining (green), with dapi (blue).
Similar to the Tuj1+ cells, the Ki-67+ cells also lack FKN expression.
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Figure 14: CX3CR1 blocking antibody increases hippocampal IL-1β levels. In 3
month old male rats treated for 28 days with the blocking antibody we found a significant increase
in IL-1β protein levels compared to non-immune IgG or Saline control animals. (††p=0.0023 Saline
vs. IgG) (***p=0.0003 saline vs. α-CX3CR1) (*p=0.039 IgG vs. α-CX3CR1) (Saline n=8; IgG n=4;
a-CX3CR1 n=5).
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Figure 15: IL-1Ra
reverses the effects of αCX3CR1. To determine if the
decrease neurogenesis caused by
blocking antibody to α-CX3CR1
was mediated by IL-1β we infused
IL-1Ra along with the blocking
antibody for 7 days of treatment.
On day 6, young adults rat were
injected with BrdU. Gray bars are
the groups that received heatinactivated IL-1Ra. White bars are
groups that received active IL1Ra. (A) In the α-CX3CR1/HI-IL1ra group, there was significantly
fewer BrdU+ cells then the three
other groups which were not
different from each other. (B) IL1ra blocked the decrease in DCX+
cells caused by α-CX3CR1. In the
non-immune IgG group IL-1Ra
(white) caused a significant
decrease in the number of DCX+
cells compared to the IL-1Ra
inactive control (grey). (C) A
representative photomicrograph of the BrdU (green) and DCX (red) double labeling. Following the
14 day infusion paradigm (see Fig.3A), (D) we found a significant (p=0.0091) decrease in the
number of CldU+ cells which were born the day before we started infusion in the α-CX3CR1 (n=4)
compared to the non-immune IgG group (n=5). (E) In the 14 day experiment, a significant
decrease (p=0.0406) was also found in the number of IdU+ cells in the α-CX3CR1 (n=4)
compared to the non-immune IgG group (n=5). (F) Quantification of the number of DCX+ cells
also demonstrated a significant (p=0.0311) decrease following treatment in the α-CX3CR1 (n=4)
compared to the non-immune IgG group (n=5).
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Figure 16: CldU colocalizes with NeuN.CldU+ cells (red) were found to co-localize with
NeuN+ cells (green) in the IgG treated group (A) and α-CX3CR1 treated group (B).
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Figure 17: FKN signaling regulates microglia activation. Quantification of the number
of OX-6+ cell, which is a marker for MHC class II, (A) we found in the rats that received the
blocking antibody with an inactive IL-1Ra (gray) a significant increase in the number of OX-6+
cells compared to the two non-immune IgG groups. (B) After 15 days of blocking antibody
treatment in the young rats a similar significant increase in the number of OX-6+ cells was found
in the young α-CX3CR1 treated rats (n=5) compared to the non-immune IgG treated rats (n=5).
(C) In the aged rats after 14 days of treatment with FKN a significant decreased (p=0.0163) the
number of OX-6+ cells was found in the α-CX3CR1 treated rats (n=6) compared to the nonimmune IgG treated rats (n=4). (D) The number of OX-6+ cells was also found to significantly
correlated with the number of IDU+ cells(r(9)=-0.7425; p=0.0219)
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Conclusions: The Role of neuroinflammation in regulating the age-related decline
in neurogenesis: could restoring the balance rescue neural plasticity
Introduction
Deteriorations in cognitive function occur as a consequence of growing old in the
absence of clear neurological damage or disease. Aging is the background in which many
neurodegenerative diseases manifest; therefore, in understanding of the age-related alterations
that occur in the central nervous system (CNS) are an important consideration when developing
therapeutic interventions for age-related neurodegenerative diseases. Age-associated memory
impairments, should not be considered unavoidable. On it’s on merit, strategies for ‘successful’
aging’ are worthy of scientific investigation.
The hippocampus is critical structure for normal memory functions. Alterations in
neural plasticity, not cell loss, appear to be responsible for the age-related alterations in
hippocampal dependent cognitive function. There are numerous subtle age-related alterations in
neural plasticity (for review see: (Burke and Barnes, 2006)). Adult neurogenesis is one form of
neural plasticity that is dramatically limited with age.
Adult neurogenesis
The majority of the neurons in the adult central nervous system (CNS) are postmitotic. In
the absence of pathology, neurons are believed to remain postmitotic, and survive thought the
lifespan of the organism. However, an ongoing neurogenesis continues to occur in two germinal
centers of the CNS: the subventricular zone (SVZ), and the subgranular zone (SGZ) of the
dentate gyrus (DG) of the hippocampus. Adult neurogenesis is a process that involves a
continuum of developmental stages. The final result of the process is that a few newly born cells
are added to the existing neuronal circuitry. Adult hippocampal neurogenesis occurs in a region
called the SGZ, which is roughly defined as a two cell diameter band on the hilus side of the
granule cell layer (GCL). Proliferation of the neural stem/progenitor cells (NPCs) produces a pool
of immature cells, the majority of which will become neurons. Following the generation of the
daughter cell, the postmitotic cell goes through an early survival phase. During this phase the
number of surviving neurons can vary greatly depending on the strain of animals used and can be
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as great as ~ 75% or as few as 25% of the amount of proliferating cells (Kempermann et al.,
1997c). Moreover, in the young adult rodent, most of the regulation of neurogenesis occurs in the
early survival phase and not in the proliferative phase (Kempermann et al., 2006). The newly born
cells the majority of which do become neurons, go through a migratory phase (Kempermann et
al., 2003b), which occurs while the cells are becoming functionally mature. The adult-born
neurons become morphologically and physiologically fully mature and indistinguishable by 6 to 8
weeks after birth in the young adult rodent (van Praag et al., 2002; Esposito et al., 2005; Zhao et
al., 2006; Toni et al., 2008). Finally, an additional phase of neurogenesis appears to be the
eventual death of the cell, as a continual turnover of cells both mature and immature is necessary
to 'make room' for the addition of more cells.
Adult neurogenesis and memory are they related?
The addition of new neurons into the hippocampus, a region of the brain important for
learning and memory, has elicited interest in understanding if and how the addition of new
neurons would contribute to cognitive function (Leuner et al., 2006; Aimone et al., 2009).
However, the involvement of neurogenesis, in cognitive function is complex. Correlations,
between genetic and environmental alterations, were initially used to justify the importance of
neurogenesis in cognitive function. For example environmental enrichment (EE) has been shown
to enhance memory and increase neurogenesis (Kempermann et al., 1997b). However, following
irradiation to block neurogenesis, the behavior improvements of EE on spatial learning in the
Morris water maze (MWM) was found to be independent of neurogenesis (Meshi et al., 2006). In
a subsequent experiment that used irradiation to block neurogenesis without EE, blocking
neurogenesis was found to impair contextual fear conditioning with no effect on MWM (Saxe et
al., 2006). Using an inducible mouse model in which NPC are selectively eliminated by overexpressing the pro-apoptotic protein Bax only in nestin expressing cells found that neurogenesis
was required for MWM but nor for contextual fear conditioning (Dupret et al., 2008).
Often the contradictions in fact support the role of neurogenesis in cognition. A recent
study by Dupret et al (2007) demonstrated that not only is the addition of new neurons into the
hippocampal circuit important for cognition but so is the removal of granule cells important for
cognition (Dupret et al., 2007). Like the hippocampus, several thousand newly generated neurons
are added to the olfactory bulb (OB) (Lledo and Lagier, 2006). In the OB, learning of olfactory
information also appears to be coupled to the survival of some newly generated neurons and the
removal of others (Mouret et al., 2008).
Despite the often contradictory findings, numerous studies have shown that the de novo
production of neurons in the hippocampus is physiologically relevant for cognitive function (For
review see: (Leuner et al., 2006; Drapeau and Nora Abrous, 2008)). From the numerous studies
that have been done the involvement of neurogenesis in cognitive function can be classified into
3 groups: 1) effects on proliferation, 2) effects on survival, and 3) effects on cell death. It appears
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that alterations in one or more of these 3 aspects of neurogenesis can impact cognition.
Neurogenesis and aging: is neurogenesis involved in age-related cognitive decline.
Neurogenesis appears to continue throughout the lifespan, however studies in rodents
describe a nearly linear decline in neurogenesis as a function of age. Despite the thousands of
new neurons that are born every day in the young adult hippocampus, with age a greater then 40
fold decrease can be seen in the number of new neurons that are added into the aged
hippocampus. A peak in neurogenesis occurs during adolescents, after which point, there is a
continuous decline in neurogenesis until senescence when very few new cells are added to the
aged brain (Ben Abdallah et al., 2008). The decline in neurogenesis has led to speculation
concerning the contribution of neurogenesis to the impairments in cognitive function that occur
during normal aging? A troubling issue arises in that the decline in neurogenesis well precedes
any age-related cognitive decline. The largest decrease in neurogenesis occurs between 7.5
months and 12 months of age in rats (Rao et al., 2006). A threshold hypothesis has been
presented to account for this discrepancy. The basic concept of the hypothesis is that the
decrease in neurogenesis with age does not impact cognition until the level of neurogenesis
reaches some physiologically minimum number of cells.
Drapeau et al. (2003) addressed this threshold hypothesis by using aged rats that are
‘good’ or ‘bad’ learners. Not all aged rats have cognitive-impairment, at least as measured by the
spatial learning task of the Morris water maze (Gallagher et al., 1993). Numerous studies over the
years have used the natural variation in cognitive function in aged rats to investigate if there are
differences in between the rats that demonstrate impaired cognition compare to the rats whose
cognitive performance is equal to that of a young rat. Drapeau et al (2003) exploited these natural
variations in cognitive function to ask the question if neurogenesis could be involved in age
induced cognitive impairments. The results of their study demonstrated that rats that were defined
as being cognitively un-impaired had increased proliferation of the NPC and more neurogenesis
then cognitively impaired rats. However, while the cognitively intact rats had more neurogenesis
than the impaired rats, the cognitively intact rats still had great deal less neurogenesis then the
young rats. Moreover, in the young rats then amount of neurogenesis did not correlated with
cognitive performance (Drapeau et al., 2003). The results of Drapeau et al. (2003) were directly
contradicted by Bizon et al. (2004) who showed that the aged cognitively impaired rats had more
neurogenesis (Bizon et al., 2004). Moreover, other reports have showed that neurogenesis does
not correlate with spatial learning (Bizon and Gallagher, 2003; Merrill et al., 2003).
Where do we put all these new neurons?
An estimated 9000 new neurons are added each day to the hippocampus (cammeron
and Mckay 2001), but the total number of neurons in the hippocampus has been shown to be
stable over the entire lifespan, including in elderly. From the first month of life, to one year of age
the number of granule cells in the dentate gyrus does increase in rodents (Bayer et al., 1982).
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However the increase in size is no where near the amount that would be expected, based upon
the number of cells born in the SGZ. Moreover, despite the decrease in neurogenesis with age
the total number of granule cells does not decrease in the aged rat. Therefore it appears that
tissue homeostasis (total number of granule cells) in the dentate gyrus appears to be tightly
regulated. To maintain tissue homeostasis neurogenesis must be coupled to a process of
programmed cell death (PCD). This process occurs in tissues thoughtout the body, but until
discovery of adult neurogenesis, the central nervous system (CNS) was believed to be exempt
from this process. In fact, excluding disease or injury, the neurons we are born with are presumed
to be the same neurons that we will die with. However, in the hippocampus and in the SVZ
neurons are born every day, requiring the homeostatic death and removal or older neurons in
these two neurogenic regions (Biebl et al., 2000).
BCL-2 (B-Cell Leukemia 2) is the prototypical member of the Bcl-2 family of apoptotic
regulatory proteins. BCL-2 is an anti-apoptotic protein. The balance between the pro vs antiapoptotic BCL-2 family members following an apoptotic stimuli determines if the cell lives or dies
(Oltvai et al., 1993). Bax and Bak are two of the many members of the pro-apoptotic of the BCL-2
family. Using neuronal cell cultures from Bak-/-Bax-/- mice it was found that NPC require Bak and
Bid to induce excitotoxic PCD; whereas, mature neurons do not require Bak and Bid to induce
PCD (Lindsten et al., 2003). Sun et al. (04) was the first to investigate the biochemical pathways
that regulate the PCD in adult-born neurons, through the use of Bax deficient mice. The Bax
deficiency resulted in an absence of apoptosis in the adult DG, without any alterations in the
production of new neurons. In the wild type mice the number of neurons in the DG remained
stable from 2 months to 12 months of age. In comparison, there was an age-dependent increase
in the number of cells in the DG in the Bax deficient mice (Sun et al., 2004). Kuhn et al. (05)
replicated the findings of Sun et al. (04) through the overexpression of BCL-2 in transgenic (Tg)
mice . The overexpression of BCL-2 reduced by did not completely block apoptosis. The
increase in neurogenesis was also not as dramatic as that seen following Bax deficiency. The
total number of cells in the GCL was also increased in the BCL-2 Tg mice (Kuhn et al., 2005).
The BCL-2 Tg mice have also been shown to have cognitive deficits (Rondi-Reig et al., 2001).
These results support the notion that the loss of neurons is important for cognition (Dupret et al.,
2007).
Microglia Regulation of cell death in developmental and adult neurogenesis
Microglia are immune cellular component and the professional phagocyte of the brains.
Recognition of pathogen associated molecular pattern (PAMPs) and is recognized by microglia
pattern-recognition receptors (PRR). The most common PAMP used experimentally, particularly
in neuroscience research, is lipopolysaccharide (LPS). LPS a major component of the outer
membrane of gram-negative bacteria and is used to induce inflammation in the CNS to
understand the involvement of the immunity in a particular condition. LPS can be very useful, as a
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way to induce a replicable and specific immune response. However, LPS induces a microbial
defense immunity, resulting in the activation of pro-inflammatory pathways, producing
inflammatory mediators including cytokines and chemokines. The response to eliminate the
‘danger signals’ does not discriminate and will also cause damage to the uninfected tissue.
Besides the PRRs, microglia also express a number of scavenger receptors that are involved in
the recognition and removal of dead cells and other cellular debris; such as Aβ.
In many ways the process of adult neurogenesis recapitulates events during embryonic
development. During development of the nervous systems, in excess of neurons are born then
ultimately survive into adulthood. (Oppenheim, 1991). It has been hypothesized that during
development the excess of cells are produced to allow for a competition between the newly born
neurons for trophic support from other neurons and glia (Oppenheim, 1991). The competition for
trophic support, results in a proportion of the cells being eliminated. The ‘pruning’ of the excess
cells, presumably by some form of PCD, leaves the cell which received the adequate trophic
support to survive and be integrated in the neuronal circuit (Oppenheim, 1991). A similar process
is believed to occur during adult neurogenesis as well.
During development the dead cells are recognized and removed phagocytes. In the brain
the dead cells are recognized by microglia and are removed (Mallat et al., 2005). The primary
‘eat-me’ signal expressed by dying cells is phosphatidylserine (PS) on the outer leaflet of the
plasma membrane of the apoptotic cells (Fadok et al., 1992). Severe developmental brain
malformations occur if microglia are not able to recognize PS due to genetic deletion of PS
receptor (Li et al., 2003). Some the ‘eat-me’ signals expressed by dying cells are shared with
PAMP, and have therefore been called, apoptotic cell associated molecular pattern
(ACAMPs)(Savill et al., 2002). While both PAMPs and ACAMPs are recognized by the
macrophage through the PRR, the response by the macrophage is distinct. Recognition of a
PAMPs by a macrophage promote an inflammatory response; whereas, recognition of an ACAMP
inhibits inflammation (Stuart and Ezekowitz, 2005). This is important for the ‘silent’ removal of the
apoptotic cells (Medzhitov, 2008).
To ensure healthy cells are not the victims of over active microglia, healthy cells present
an additional class of inhibitory signals which have been called ‘don’t eat me’ signals or self
associated molecular patterns (SAMP). The SAMPs expressed by neurons include CD200,
CD47, and fractalkine among others.
Microglia are not only involved the phagocytosis of the apoptotic cells, but also contribute
to demise of the apoptotic cells. If the dying cell does not present the ‘kill-me’ signals, PCD can
be stopped and the cells will survive (Hoeppner et al., 2001; Reddien et al., 2001). During
development two models have shown that microglia responded to the 'kill-me' signal presented by
neurons with a respiratory release of ROS to kill the cells. This has been shown in the cerebellum
and the hippocampus (Marin-Teva et al., 2004; Wakselman et al., 2008). In the hippocampus the
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process was CD11b and DAP12 mediated (Wakselman et al., 2008). As described earlier, the
removal of excess neurons is important to cognitive function as the addition of neurons. Microglia
have an important role in the removal (pruning) of excess neurons.
Inflammation and adult neurogenesis
Two seminal studies, published simultaneously, a number of years ago showed that
inflammation tightly regulates neurogenesis (Ekdahl et al., 2003; Monje et al., 2003). Ekdahl et
al. (03) used LPS that they delivered into the cortex continuously by an osmotic mini pump. After
28 days of LPS there was a dramatic activation of ED-1+ cells. ED-1 (CD68) is a member of the
scavenger receptors, which is highly expressed on monocytes and some tissue macrophages.
The expression of ED-1 on microglia is normally absent, but can be induced following an
inflammatory insult, which is what was found after 28 days of intracortical infusion of LPS. In the
young adult rat, LPS-induced inflammation resulted in an 85% reduction in the number of new
neurons born during the inflammatory insult (Ekdahl et al., 2003). Monje et al. (03) also found
that LPS given systemically also cause in increase in microglia activation and a decrease in
neurogenesis, which could be prevented by the nonsteroidal anti-inflammatory drug (NSAID)
indomethacin. Toll-like receptor (TLR)-4 is the specific receptor for LPS. Expression of TLR-4 in
CNS glial cells was found to be limited to microglia (Lehnardt et al., 2002). NPC and mature
neurons have been shown to express TLR-4 (Rolls et al., 2007; Tang et al., 2007); thus, it is
possible that the anti-neurogenic effects of LPS could be independent of microglia.
While TLRs (particularly TLR-4) often acts a co-receptor in many immune responses, the
immune response to bacteria, virus, or parasite, is quite different then that started from tissue
damage. Monje et al (03) found that inflammation was also at least in part responsible for the
decrease in neurogenesis after irradiation. Following irradiation there was an increase in
microglia activation that could be prevented by treatment with NSAID. The treatment with the
NSAID was also able to prevent anti-neurogeneic effects of irradiation. Microglia besides being
responsible for protecting the CNS from invading pathogens, are also important for removing
cellular debris. Microglia are the professional phagocytes of the brain.
Microglia would appear to be the optimal cell to regulate neurogenesis. Microglia perform
3 key functions that would make them key in regulating neurogenesis. First microglia have the
potential to be neurotoxic though the production of reactive oxygen species thereby being
involved in the removal of mature or immature cells(Marin-Teva et al., 2004; Wakselman et al.,
2008). Microglia are also important for the phagocytosis of the dead cells (Mallat et al., 2005).
The second way that microglia can be involved in regulating neurogenesis is through the
production of cytokines. This is particularly true for the key innate cytokines IL-1β and TNF-α, with
activated microglia being the major source of TNF-α and IL-1β in the CNS (Gebicke-Haerter,
2001)(Shaftel et al., 2008). At low concentrations TNF-α, induced proliferation of NPC, but at
higher concentrations TNF-α induced PCD (Bernardino et al., 2008). NPC cultures have been
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shown to have constitutively express the TNF-α RI and TNFRII (R. E. Iosif et al., 2006). TNF-α
induced apoptosis in the NPC is dependent on TNFRI (Sheng et al., 2005). IL-1β can also directly
suppress neurogenesis by blocking the production of cyclic dependent kinesis (Iosif et al., 2006;
Koo and Duman, 2008). Inflammation also alters the way the new neurons integrate into the
existing neuronal circuit (Jakubs et al., 2008). The third way in which microglia can regulate
neurogenesis is by a pro-repair/pro-neurogenic mechanism. Microglia are able to produce a
number of growth factors including IGF-1 and BDNF which have been shown to promote
neurogenesis (For review see:(Ziv and Schwartz, 2008)).
Age-related cognitive impairment: is it a numbers game?
The dramatic decrease in neurogenesis with age has led to much speculation concerning
the extent in which the decline in neurogenesis contributes to age-related cognitive impairments.
During the 1990’s, when adult neurogenesis was accepted by the scientific community the
commonly held view was the total number of newly formed mature neurons would correlate with
cognitive performance. To this end, the age-related decline in the total number of new neurons
was believe to, at least impart contribute to the cognitive decline that occurs during the course of
normal aging. As discussed earlier, the result of Drapeau et al. (2003) suggest the total number
of new neurons may indeed be critical for cognitive performance. However, it has become
increasingly clear that in the young adult where the addition of new neurons is in abundance, it is
not so much that total number of cells that is important, but the experience-dependent regulation
of addition and removal of neurons that is important for certain types of cognitive function. The
same dynamic holds true in the aged brain, where rats that are aged-unimpaired demonstrate
experiences dependent addition and removal of new neurons (Drapeau et al., 2007).
The primary cause for the decrease in neurogenesis in aging is due to a decrease in
proliferation of the NPC (Hattiangady and Shetty, 2008). During development an excess of cells
are born with the ‘fittest’ cell surviving. A similar process occurs in young adult, where the majority
of the experience-dependent regulation of neurogenesis occurs as a result of survival of the
‘fittest’ cell. If an ‘unfit’ cell is forced to survive by inhibiting PCD memory has been shown to be
impaired (Dupret et al., 2007). What about with age where the majority of the regulation of the
number of new neurons occurs at the proliferation stage and not at the survival phase? Could the
change at which point neurogenesis is regulated be responsible for the age-related cognitive
decline? With fewer cells, there is less competition, which could allow the survival of an ‘unfit’ cell.
There is no direct experimental evidence to support or reject either hypothesis. However, Bizon et
al. (2004) found that aged-impaired rats had more new neurons. The results of Bizon et al. (2004)
has led to the suggestion that neurogenesis is not involved in neurogenesis. However, in
alternative hypothesis of the findings of Bizon et al. (2004) could be that in the aged-impaired rats
‘unfit’ cells survive. The survival of ‘unfit’ cells could be a compensatory mechanism in the aged
impaired rats to overcome for losses in other forms of synaptic plasticity. Alternatively, the aged70

impaired rats may be deficient in the removal of ‘unfit’ cells resulting in abnormal connections that
impair memory.
Conclusion
It is known that with aging and age-related neurodegenerative diseases, there is a state
of chronic inflammation. The cause of the chronic inflammation in aging is not clear. However, the
age-related increase inflammation has been shown to impair neurogenesis by decreasing
proliferation, survival, and integration of new born neurons. The experience dependent,
integration and removal of neurons, appears to be important for cognitive attributes of
neurogenesis (Aimone et al., 2009). It is plausible, that with age inflammation alters the ability of
the new neurons to properly integrate into the existing neuronal circuit in an experiencedependent manner. The total number of new neurons may not be the best predictor of the
involvement of neurogenesis in age-related cognitive impairment. Alternatively, the ability of the
new neuron to be regulated in an experience-dependent manner appears most important for the
neural plasticity afforded by neurogenesis. The previous three chapters, demonstrated, that
inflammation does contribute to the age-related decline in neurogenesis. Figure 19 demonstrates
a cartoon summary of the findings of the previous three chapters. In the future, it would be
informative to determine if restoring the inflammatory balance in humans could forestall agerelated cognitive impairments.
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Figure 18: How neuroinflammation can modulate adult hippocampal neurogenesis.
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